

**UNIVERSIDADE ESTADUAL PAULISTA “JÚLIO DE MESQUITA FILHO”**

**FACULDADE DE MEDICINA**

**CÂMPUS DE BOTUCATU**

**CARCINOGENESE DE MAMA EM MODELO EXPERIMENTAL DE  
EXPOSIÇÃO GESTACIONAL, JUVENIL E ADULTA AO  
HERBICIDA DIURON [3(3,4-DICLOROFENIL) 1,1, DIMETIL URÉIA]  
EM FÊMEAS SPRAGUE-DAWLEY**

**TONY FERNANDO GRASSI**

Tese apresentada ao Programa de Pós-Graduação em Patologia da Faculdade de Medicina de Botucatu, Universidade Estadual Paulista – UNESP para obtenção do título de Doutor em Patologia.

**Botucatu - SP**

**2010**

**UNIVERSIDADE ESTADUAL PAULISTA “JÚLIO DE MESQUITA FILHO”  
FACULDADE DE MEDICINA  
CÂMPUS DE BOTUCATU**

**CARCINOGENESE DE MAMA EM MODELO EXPERIMENTAL  
DE EXPOSIÇÃO GESTACIONAL, JUVENIL E ADULTA AO  
HERBICIDA DIURON [3(3,4-DICLOROFENIL) 1,1, DIMETIL  
URÉIA] EM FÊMEAS SPRAGUE-DAWLEY**

**Doutorando: Tony Fernando Grassi**

**Orientador: Prof. Dr. Luís Fernando Barbisan**

**Co-orientador: Prof. Dr. João Lauro Viana de Camargo**

Tese apresentada ao Programa de Pós-Graduação em Patologia da Faculdade de Medicina de Botucatu, Universidade Estadual Paulista – UNESP para obtenção do título de Doutor em Patologia.

**Botucatu - SP**

**2010**

FICHA CATALOGRÁFICA ELABORADA PELA SEÇÃO DE AQUIS. E TRAT. DA INFORMAÇÃO  
DIVISÃO TÉCNICA DE BIBLIOTECA E DOCUMENTAÇÃO - CAMPUS DE BOTUCATU - UNESP  
BIBLIOTECÁRIA RESPONSÁVEL: ROSEMEIRE APARECIDA VICENTE

Grassi, Tony Fernando.

Carcinogênese de mama em modelo experimental de exposição gestacional, juvenil e adulta ao herbicida Diuron [3 (3,4-Diclorofenil) 1,1, Dimetil uréia] em fêmeas Sprague-Dawley / Tonny Fernando Grassi. – Botucatu, 2010

Tese (doutorado) – Faculdade de Medicina de Botucatu, Universidade Estadual Paulista, 2010.

Orientador: Prof. Dr. Luis Fernando Barbisan

Co-orientador: Prof. Dr. João Lauro Viana de Carmargo

Assunto CAPES: 40100006.

1. Glândulas mamárias. 2. Carcinogenese. 3. Pesticidas. 4. Rato – Reprodução.

Palavras-chave: Carcinogênese mamária; Diuron; Exposição gestacional/lactacional/juvenil/adulta; Praguicida; Sprague-Dawley.



*Dedicatória*

Aos meus pais Eugênio Grassi e Rosângela Maria Grassi e a minha irmã Pamela Giovana Grassi, por compreenderem os meus anseios, sonhos e por me impulsionarem a continuar neste caminho através do mais belo sentimento que o homem pode ter, o Amor, que nunca desiste, tudo suporta e tudo crê. Obrigado por entenderem minhas ausências, as caras feias, a falta de paciência e tantos outros sentimentos ao longo desses anos. Obrigado pelas lutas de cada dia, são tantas...

Não é possível transformar todos os meus sentimentos por vocês aqui, em palavras...

A vocês, o meu amor, este trabalho, obrigado!

Também aos nossos animais de estimação, Julie e Mel... pelos momentos de companhia e distração

“O que há de maravilhoso numa casa não é ela abrigar-nos, nem aquecer-nos, nem nós possuímos as suas paredes; o que é maravilhoso é ela ter depositado em nós estas provisões de doçura, é ela formar, no fundo do nosso coração, este maciço obscuro, donde brotam, como águas de uma fonte, os sonhos...”

(Saint-Exupéry)

Senhor, este momento e todo este trabalho, é parte de tudo que me reservas. Longos quatros anos e muitos desafios e o desânimo que hora me visita. Já nem sei dizer os caminhos que percorri neste tempo e quantos obstáculos superados graças a Tua presença e fidelidade ímpar. Agradecer-Te seria muito pouco. Obrigado por tudo aquilo que me proporcionou e me proporciona, por permitir chegar até aqui. Obrigado por me guardar debaixo de tuas asas e assim como o passado e presente, que o futuro esteja guardado em Tuas mãos.

Minha eterna gratidão

“Com tua mão, ó meu Senhor Segura a minha... Dois não me atrevo a um passo só Sem teu amparo, sem teu apoio... Eu não darei, eu só iria fraquejar Eu andaria a vacilar, sem tua mão a me sustentar... Mas se tua mão me segurar, Eu correrei até... voar..... subirei apoiado em ti”

(Sueley Façanha)

Delas perdas necessárias e constates que todos nós passamos. Com elas aprendemos muito. Aprendemos a olhar a vida como um grande milagre que acontece a cada momento, a cada pulsar do coração e a sua fragilidade e reservas. Aprendemos com quem passou por aqui e hoje vive na lembrança com sabor de saudade. Obrigado por fazer parte da minha história!

Também não poderia de deixar de lembrar nosso animal de estimação, Yeska... a nossa pintada... chegou branca e o tempo se encarregou de colocar as suas pintas negras pelo corpo; grandes momentos...

“... a Saudade eterniza a presença de quem se foi e com o tempo esta dor se aquieta, se transforma em silêncio que espera pelos braços da vida um dia reencontrar...”

(Fábio de Melo)



*Agradecimento Especial*

Ao Prof. Dr. Luís Fernando Barbisan, antes de ser orientador, um amigo que tive a  
graça de conhecer e tê-lo como orientador ao longo desses seis anos, entre  
mestrado e doutorado. Obrigado pela lapidação do meu desenvolvimento  
científico.

Tenho muito a te agradecer...

Obrigado por cada momento de partilha, amizade, por sempre estar presente.

Agradeço ainda pelos ensinamentos e pelo seu exemplo de dedicação

Obrigado pela confiança ao longo deste tempo...

“Feliz aquele que ensina o que sabe e aprende o que ensina”

(Cora Coralina)

Ao Prof. Dr. João Lauro Viana de Camargo pela amizade e seus ensinamentos.  
Obrigado pela sua orientação em tantos momentos, pelo exemplo de caráter científico e por permitir a utilização do laboratório - Núcleo de Avaliação do Impacto Ambiental sobre a Saúde Humana TOXICAM e seus equipamentos.  
Meus eternos agradecimentos.

"Aprender é a única coisa de que a mente nunca se cansa, nunca tem medo e nunca se arrepende."

(Leonardo da Vinci)



## *Agradecimientos*

À Ziza Fernandes

Por ser minha referência na vida musical. Obrigado por ser a “ressurreição para o meu ser” em tantos momentos na minha vida e pela amizade incondicional que não busca interesse. A você, todo meu respeito, minha admiração e meus sentimentos.

É especial na minha vida!

Obrigado por tanto ensinar...

...Vitória é o que vem depois da cruz e ninguém há de condenar o que Teu amor tocar...

(Ziza Fernandes)

Aos amigos de convivência diária: João Francisco Lozano Luvizutto; Marize de Lourdes Marzo Solano, Meire França Martinez, Merielen Garcia Nascimento e Renata Aparecida Martinez Antunes Ribeiro Vieira pelas horas, dias e anos que passamos juntos. Obrigado pela amizade, por partilhar horas de refeições, artigos, discussões e tantos assuntos aleatórios além das progressões e modificações que fizemos em nosso ambiente de trabalho... passamos mais tempos juntos do que passamos com nossas famílias. Obrigado por tudo e este trabalho não é o ponto final...

Aos amigos Gisele Aparecida Dionísio Lopes; Kelly Silva Furtado, Joyce Regina Zapaterini Lucas Tadeu Bidinotto, Marcos Correa Dias, Nelci Antunes de Moura e também ao mais novo integrante do grupo do Dr. Barbisan, Marcos Aurélio de Aguiar e Silva, obrigado pela amizade e por toda ajuda nos experimentos.

À dupla Tânia Alice Andrade e Vânia Soler, secretárias do Curso de Pós-Graduação em Patologia, pela amizade, pelos sorrisos, por toda atenção. Obrigado por sempre atenderem as minhas solicitações.

Aos amigos Glória Aparecida Rodrigues, Ivana Rosa Loli Georgete, Juliana Semim Cavalcheiro e Paulo César Georgete pela amizade, por cuidar e nos ajudar com os nossos animais no biotério.

Aos amigos Maria Luiza Falaguera Ardanaz e Paulo Roberto Cardoso pela amizade ao longo desses anos, por me ensinar tantas coisas na parte de histologia e pelo preparo do nosso material histológico. Esse trabalho também é de vocês!

Aos colegas do Toxicam Alexandre Domingues Ana Paula Ferragut Cardoso, Bianca Ferrucio, Cristina Dorico, Gabrielli Brianezi, Mitscheli Sanches da Rocha,

Shadia Muhammad Ihlasch e Viviane Mattos Pascotto pela amizade, reuniões e confraternizações.

À Profa. Dra. Carla Adriene da Silva Franchi pelos anos de amizade. Fazemos parte da antiga “geração” deste laboratório!

À Profa. Dra. Maria Aparecida Marchesan Rodrigues pela amizade e por fazer parte deste trabalho com suas orientações, ensinamentos e paciência. Obrigado!

À Profa. Dra. Daisy Maria Fávero Salvadori, Profa. Dra. Maria Aparecida Custódio Domingues, Profa. Dra. Maria Luiza Cotrim Sartor de Oliveira, Profa. Dra. Mariângela Esther Alencar Marques e Profa. Dra. Noeme Sousa Rocha, pela amizade e pela disponibilidade em ajudar nas dúvidas.

À Profa. Wilma De Grava Kempinas, Arielle Cristina Arena, Glaucia Scantamburlo Alves Fernandes, Juliana Elaine Perobelli, Marina Trevizan Guerra pela amizade, ensinamentos, acompanhamento na parte experimental da reprodução e por fazer parte deste trabalho. Obrigado por tudo!

À Celene Maria Gondin, Luiz Fernando Franchi e Marcos Roberto Franchi pela amizade e por tantas vezes me atenderem na realização no processo de recuperação antigênica.

As Coordenadoras do Curso de Pós-Graduação, Dr<sup>a</sup> Denise Fecchio e Dra. Márcia Guimarães da Silva pela amizade, Obrigado.

Aos Professores e Funcionários do Departamento de Patologia pela amizade.

Aos amigos pós-graduandos e aos que já não são mais, mas que continuam por perto, pela amizade e por compartilhar a vida científica.

Aos amigos que se tornaram laços indissolúveis em minha vida, Alessandra Medeiros, Amanda Camargo, Carolina Aparecida Lopes, Elaine Aparecida de Camargo, Elaine Almeida, Fabiano Augusto de Medeiros, Telma Marques Medeiros, Renato Medeiros, Fernanda Davan Rocha, Michael Almeida pela amizade e por tantos momentos vividos. Obrigado por fazer parte da minha vida, da minha família, da minha história.

Aos amigos do vôlei pela amizade e horas de quadra e distração.

Aos meus familiares pelo incentivo para continuar a ir sempre em frente. Pelas festas e diversões.

Aos amigos da Sessão de Pós-Graduação, Andrea Paula Longo Devidé, Janete Aparecida Herculano Nunes Silva, Lillian Cristina Nadal Bianchi Nunes, Nathanael Pinheiro Salles e Regina Célia Spadin, por sempre estarem disponíveis e atenderem as minhas solicitações. Obrigado por esses anos de amizade.

À Fundação de Amparo à Pesquisa do Estado de São Paulo FAPESP pela concessão da Bolsa/Reserva Técnica.

E a todos que contribuíram direta ou indiretamente na realização desse trabalho.

## Aos Animais

“Foste um instrumento de nosso aprendizado?”.

Foste apenas um objeto de experiência?

Não!!!

Foste para nós, vítimas solicitadas pela ciência, para benefício da humanidade, porém, apesar do teu olhar mudo e de não teres a permissão da palavra, isso não nos impedirá de dizer-te sempre:

Muito Obrigado!

(Desconhecido)



## *Índice*

## Índice Geral

Índice de Tabelas .....	ii
Índice de Figuras .....	iii
Índice de Anexos .....	v

### Capítulo I

1. Revisão da Literatura .....	1
2. Referências Bibliográficas .....	10
3. Objetivo .....	21

### Capítulo II

#### Artigo Científico I

Abstract .....	23
1. Introduction .....	24
2. Material and Methods .....	28
2.1. Chemicals .....	28
2.2. Experimental Design .....	28
2.3. Hormone analysis and tissue proceeding for histology .....	29
2.4. PCNA, caspase-3, p63, RE, bcl-2 and bak immunostaining .....	30
2.5. Statistical Analysis .....	32
3. Results .....	33
3.1. Mortality, body and organ weights, food consumption and hormonal analysis .....	33
3.2. Histopathologic and immunohistochemical analysis .....	34

<b>4. Discussion</b>	36
<b>5. Acknowledgments</b>	42
<b>6. References</b>	43
<b>Legend for Figures</b>	52
<b>Tables</b>	55

## **Capítulo III**

### **Artigo Científico II**

<b>Abstract</b>	60
<b>1. Introduction</b>	61
<b>2. Material and Methods</b>	64
2.1. Animals and Treatments	64
2.2. Reproductive organs development and function	65
2.1. External signs of puberty onset and estrous cycle	65
2.2.2. Analysis of reproductive organs	66
2.2.3. Hormonal analysis	67
3. Effects of Diuron exposure in early life stage on mammary gland development and tumorigenesis	67
3.1. Analysis of the mammary gland morphology and function	67
3.2. Mammary carcinogenesis assay	69
4. Statistical Analysis	70

<b>3. Results</b>	71
3.1. Effects of early life Diuron exposure on dams (F0) and females offspring	71
3.2. Effects of early life Diuron exposure on reproductive and mammary parameters in female offspring	71
3.3. Effects on early life Diuron exposure on mammary carcinogenesis susceptibility	73
<b>4. Discussion and Conclusions</b>	75
<b>5. Acknowledgments</b>	80
<b>6. References</b>	81
<b>Legend for Figures</b>	90
<b>Tables</b>	93
<b>Conclusões Gerais</b>	98
<b>Anexos</b>	101

# Índice de Tabelas

## Capítulo II

### Artigo Científico I

<b>Table 1</b> - Final body weights, body-weight gain, food and Diuron consumption and feed efficiency of different experimental groups at the end of the 25-week experiment.....	55
<b>Table 2</b> - Organ relative weights of the different experimental groups at the end of experiment.....	56
<b>Table 3</b> - Hormonal plasma levels and mammary tumor data of DMBA-initiated groups .....	57
<b>Table 4</b> - Growth kinetic and expression immunohistochemical of biomarkers in mammary neoplasms from DMBA-initiated groups.....	58

## Capítulo III

### Artigo Científico II

<b>Table 1</b> - Reproductive outcomes from dams and female offspring rats in Diuron-treated and non-treated groups.....	93
<b>Table 2</b> - Assessment of estrous cycle length and frequency of each phase over a 15-day period of evaluation in the female offspring on PND 60.....	94
<b>Table 3</b> - Body weight, absolute and relative organ weights and ovarian and uterus analysis in the female offspring (PND75) in estrus phase.....	95
<b>Table 4</b> - Data from body weights, body-weight gain and ovary and uterus relative weights after week 25 of DMBA administration.....	96
<b>Table 5</b> - Data from mammary tumor analysis in DMBA-initiated groups obtained during experimental period.....	97

## Índice de Figuras

### Capítulo I

#### Artigo Científico I

- Figure 1** – Evolution of body weight in different groups during the experimental period.....53
- Figure 2** - Immunohistochemically or HE-stained sections of mammary tumors from DMBA-initiated rats:.....54

### Capítulo III

#### Artigo Científico II

- Figure 1** - Hormonal serum levels: PND 51- Estradiol (pg/ml) and Progesterone (ng/ml); PND 75- LH (ng/ml) and FSH (ng/ml).....91
- Figure 2** - Mammary gland sections from female offspring rats at PND 51.....92

### Anexos

- Figura 1** – Estrutura molecular do Diuron.....110
- Figura 2** – Delineamento Experimental I – Exposição Adulta .....114
- Figura 3** - Delineamento Experimental II – Exposição gestacional, lactacional e juvenil.....115

## Índice de Anexos

<b>Anexo 1 – Artigo Científico: Co-autoria: Potential effects of the herbicide Diuron on mammary and urinary bladder two-stage carcinogenesis in a female Swiss mouse model.....</b>	<b>101</b>
<b>Anexo 2 – Figura 1 - Estrutura molecular do Diuron.....</b>	<b>110</b>
<b>Anexo 3 – Certificado do Comitê de Ética em Experimentação Animal.....</b>	<b>111</b>
<b>Anexo 4 – Alteração do título do Projeto de Pesquisa.....</b>	<b>112</b>
<b>Anexo 5 – Atestado de Saúde Animal.....</b>	<b>113</b>
<b>Anexo 6 - Figura 2 – Delineamento Experimental I – Exposição Adulta...</b>	<b>114</b>
<b>Anexo 7 - Figura 3 - Delineamento Experimental II – Exposição gestacional, lactacional e juvenil.....</b>	<b>115</b>



## *Capítulo I*

### *Revisão de Literatura*

## 1. Revisão de Literatura

O câncer de mama é a neoplasia mais freqüente entre mulheres e a principal causa de morte entre mulheres de todo o mundo e sua etiologia não é totalmente conhecida.<sup>1</sup> Dos casos de câncer diagnosticados em mulheres, 22% dos casos novos/ano, são de mama. Na população mundial, a sobrevida média após cinco anos é de 61%. No Brasil, dados de 2008 do Instituto Nacional do Câncer (INCA) demonstram que 49.400 mulheres seriam acometidas pelo câncer de mama e com risco estimado de 51 casos a cada 100 mil mulheres. Já nos EUA, a estimativa para 2009 é de 192.370 (mulheres), 1.910 (homens) e com mortalidade de 40.170 (mulheres) e 440 (homens). (U.S. National Câncer Institute).

Como uma doença altamente heterogênea é representada por neoplasias que possuem história natural diversa, histologia complexa e resposta variável as terapias convencionais (quimioterapia, braquioterapia e radioterapia).<sup>2</sup> Atualmente, mesmo nos países em desenvolvimento, que tradicionalmente apresentavam baixa incidência, vêm se observando aumento nas taxas de incidência e mortalidade por câncer de mama entre as mulheres<sup>3</sup>. Os eventos moleculares associados ao processo de carcinogênese mamária, incluindo a iniciação, promoção e progressão, não estão bem estabelecidos e muitas alterações genéticas têm sido descritas.<sup>4,5</sup> Essas alterações compreendem mutações, amplificações e deleções gênicas, envolvendo oncogenes e genes supressores tumorais, entre eles, os genes receptores de

estrógenos e erb-B2 (HER2/neu). O uso de ferramentas para o estudo da expressão gênica tornou-se, também, fundamental para o entendimento dos eventos moleculares envolvidos nessa complexa enfermidade.<sup>6,7</sup>

Segundo a *American Cancer Society* (2002),<sup>8</sup> mutações gênicas específicas estão envolvidas em uma pequena porcentagem (5%) de todos os casos documentados de câncer de mama. Além disso, 50% dos casos de câncer de mama podem ser atribuídos a fatores de risco que incluem idade, estilo de vida e história familiar e reprodutiva.<sup>9,10</sup> Dois fatores exógenos principais têm participação importante na patogênese do câncer de mama: a exposição a agentes químicos ambientais e o consumo de fitoestrógenos na dieta.<sup>9,11,12</sup>

Muitas das neoplasias que ocorrem no ser humano são casualmente atribuídas à exposição a poluentes ambientais, pesticidas, drogas, luz ultravioleta, radiação e ao cigarro (tabaco).<sup>13</sup> Atualmente, a exposição a agentes tóxicos ambientais, entre eles, os pesticidas agrícolas tem sido correlacionada com o aumento do risco de desenvolvimento de câncer de mama.<sup>9,11,12</sup>

As neoplasias de mama surgem espontaneamente em algumas espécies animais, como por exemplo, cães, ratos e camundongos. Por razões práticas, a maioria dos estudos experimentais de carcinogênese mamária são conduzidos em roedores devido à baixa frequência de tumores espontâneos observados em estudos de longa duração.<sup>14,15</sup> A possibilidade do desenvolvimento de neoplasias de mama em roedores tem sido utilizada para avaliar o potencial cancerígeno de compostos químicos específicos.<sup>16,17,18</sup> Tumores induzidos pela

administração de cancerígenos químicos constituem ferramentas úteis para o entendimento das múltiplas etapas da carcinogênese e como linha de base para testes do potencial cancerígeno de agentes químicos e para avaliação do risco.<sup>14,19</sup>

As neoplasias mamárias quimicamente induzidas são, em geral, carcinomas hormônio-dependentes. A incidência, multiplicidade e tipos de tumores mamários são influenciados por idade, tempo de exposição ao cancerígeno, história reprodutiva, desregulação endócrina, dieta e outros fatores que alteram o desenvolvimento e o grau de diferenciação da glândula mamária.<sup>20-23</sup> As substâncias químicas mais utilizadas nos modelos experimentais de indução da carcinogênese mamária em fêmeas de ratos e camundongos são a 7,12-dimetilbenz(a)antraceno (DMBA) e a N-metil-N-nitrosourea (MNU) e as linhagens de eleição são fêmeas da linhagem de ratos Sprague-Dawley e Wistar-Furth.<sup>24,25</sup> Estudos experimentais indicam que substâncias ambientais como os pesticidas (DDT, policlorinadobifenis, 4-nonyphenol, 4-octylphenol e atrazina) podem promover neoplasias de mama em roedores.<sup>26,27</sup> O herbicida atrazina (2-cloro-4-etilamino-6-isopropilamino-s-triazina), por exemplo, vem sendo muito estudado pelo fato de exibir efeitos adversos sobre o sistema endócrino e gonadal, particularmente, no centro de controle hipotalâmico da função hipófise/ovário e sobre a tireóide, por retardar o início da puberdade, gravidez e espermatogênese<sup>28</sup>, além de

aumentar a da incidência de tumores mamários e pituitários em fêmeas Sprague-Dawley expostas ao herbicida atrazina.<sup>29,30</sup>

Nos ratos, as glândulas mamárias são formadas inicialmente pelo espessamento ectodérmico das cristas mamárias que darão origem ao broto mamário primário por volta do 12º ao 14º dia gestacional (DG). A partir do 16º DG até o nascimento, as células epiteliais do broto mamário se desenvolvem e se ramificam e o mesênquima adjacente começa a se diferenciar para formar o suporte para a ramificação ductal.<sup>31,32,33</sup> O crescimento da glândula mamária é isométrico (isto é, proporcional ao crescimento corpóreo), mas se torna alométrico (isto é, duas a três vezes maiores que o crescimento corpóreo) durante o período pós-natal antes do início da puberdade, e exponencial durante a puberdade.<sup>31,32,33</sup> Os períodos compreendidos entre o 16º-20º dia DG e a puberdade são os mais críticos para o desenvolvimento mamário e que podem ser influenciado por vários fatores, entre eles os agentes químicos atrazina e dioxinas (TCDD).<sup>34-38</sup>

Diversas substâncias utilizadas na agricultura são agentes teratogênicos, mutagênicos e cancerígenos.<sup>39,40</sup> A exposição a essas substâncias, em especial aos pesticidas, ocorre não somente por trabalhadores rurais e agricultores que manipulam diretamente estes compostos (exposição ocupacional), mas, também, pela população em geral por meio da ingestão de água e alimentos contaminados (exposição acidental). Portanto, a avaliação do potencial toxicológico (periculosidade) de pesticidas pode fornecer informações

importantes para a implementação de políticas governamentais de saúde pública que regularizem sua utilização em níveis seguros para exposição humana.<sup>41,42</sup>

Dentre as variedades de pesticidas encontradas no mercado de defensivos agrícolas, o Diuron [3(3,4-diclorofenil) 1,1, dimetil uréia], herbicida derivado da uréia, é utilizado para o controle seletivo de plantas daninhas nas culturas de frutas, algodão, cana-de-açúcar, alfafa e trigo, sendo prontamente absorvido pelas raízes e folhas das plantas daninhas, mostrando ação de contato e residual. Este herbicida é classificado como sendo de toxicidade nível de II a IV, dependendo do tipo de formulação<sup>43</sup>, e se trata de uma combinação não-iônica com moderada solubilidade em água (22 a 42 mg/L a 20°C). Diuron é estável nos processos de oxidação e decomposição química, persistindo no solo por longo período.<sup>44,45</sup>

O Diuron é absorvido com facilidade pelo trato gastrointestinal e sistema respiratório, sofre metabolismo hepático (hidroxilação e N-dealquilação), e a maioria de seus metabólitos é encontrada na urina de animais expostos.<sup>46</sup> Este herbicida pertence à classe dos indutores de enzimas do sistema de oxidases de função mista (enzimas do citocromo P450), aumentando o conteúdo enzimático do sistema P450 em aproximadamente 50%, quando comparado a pesticidas similares.<sup>47</sup>

Em roedores, os herbicidas derivados de uréia apresentam baixa toxicidade sistêmica. O Diuron apresenta a dose letal (DL50) de 1017 mg/kg

em ratos jovens, de 437 mg/kg em ratos tratados com dieta deficiente em proteínas, ou de 2390 mg/kg em ratos tratados com dieta rica em proteínas.<sup>48</sup> Em estudos experimentais, o Diuron causa irritações oculares em coelhos expostos<sup>49</sup> e fetotoxicidade e aumento de malformações em ratos.<sup>50</sup> O Diuron foi identificado como agente iniciador da carcinogênese de pele em camundongos.<sup>51</sup>

Em dois estudos de toxicidade oral em ratos e cães (durante nove meses a dois anos) foram registrados resíduos de Diuron, especialmente no fígado e rins.<sup>52</sup> Os principais efeitos tóxicos da ingestão crônica de Diuron foram a perda de peso e anormalidades em sangue, fígado e baço.<sup>46</sup> Nesses estudos as doses médias finais testadas foram de 0, 0,625, 3,125, 6,25 e 31,25 mg/kg de peso corpóreo (p.c.) por dia durante dois anos para cães da raça Beagle (dois machos e três fêmeas) e de 0, 1,25, 6,25, 12,5 ou 125 mg/kg de p.c. por dia para ratos (machos e fêmeas). Na concentração de 125 ppm (dose de 3,125 mg/kg em cães e 6,25 mg/kg em ratos) foram observados traços de pigmentos anormais no sangue em alguns animais, embora a incidência não tenha sido significativa. Na concentração de 250 ppm (6,25 mg/kg em cachorros e 12,5 mg/kg em ratos), foram observadas alterações hematológicas, perda de peso, hemosiderose no fígado e hiperplasia eritróide. Nesses estudos de toxicidade crônica não houve evidência de carcinogenicidade do Diuron.<sup>46, 52</sup>

O Diuron não mostrou atividade mutagênica na maioria dos testes *in vitro*, com ou sem ativação metabólica.<sup>53</sup> Entretanto, mutagenicidade positiva foi relatada em teste com *Salmonella typhimurium* com ativação metabólica e em ensaios de biosíntese de DNA testicular<sup>54</sup> O Diuron foi negativo em dois testes *in vitro* com células de mamíferos, o de mutação gênica em células de ovário de hamster chinês e o de síntese não programada de DNA (UDS) em hepatócitos de rato.<sup>55</sup> Em testes *in vivo*, a administração do Diuron nas concentrações de 170 e 340 mg/kg de peso corpóreo, induziu a formação de micronúcleo em medula óssea de camundongos após 30h e 48h<sup>56</sup> e mutações dominantes letais em camundongos Swiss<sup>57</sup>, além de efeitos clastogênicos em ratos.<sup>55</sup>

Estudos reprodutivos de três gerações consecutivas mostraram que a reprodução de ratos não foi afetada com doses diárias de 6 mg/kg de peso corpóreo, porém esta dose foi fetotóxica e causou redução de peso corpóreo nas proles F2 e F3. O Diuron não apresentou atividade teratogênica em ratos, mas mostrou atividade fetotóxica para proles de fêmeas expostas à dose diária de 250 mg/kg de peso corpóreo. Este efeito foi caracterizado pelos pesos fetais diminuídos, costela e ossos menores e anomalias observadas. Os mesmos efeitos foram observados na dose diária de 125 mg/kg peso corpóreo, mas em incidência não significativa.<sup>50,58</sup>

A Agência Internacional de Pesquisa em Câncer (IARC, Lyon, França) considerou o Diuron como prioritário para ser analisado quanto ao potencial

de carcinogenicidade para seres humanos, em decorrência de seus possíveis efeitos cancerígenos e mutagênicos observados em animais experimentais.<sup>59</sup> Mais recentemente, em um relato publicado pela Agência de Proteção Ambiental (USEPA) americana, o Diuron foi considerado como provável cancerígeno para o ser humano em decorrência de resultados de estudos de carcinogenicidade de longa duração.<sup>60</sup> Estes resultados, no entanto, não estão disponíveis, pois se trata de propriedade industrial designados ao registro comercial (Bayer). Deste modo, agências de regulamentação de outros países, incluindo o Brasil, têm que se basear nas informações da EPA para definir sua regulamentação própria.

Em estudos de longa-duração foi observado que o Diuron aumenta a incidência de alguns tipos de tumores em camundongos NMR1 e em ratos Wistar.<sup>60</sup> O Diuron administrado na ração (maior concentração, 2500 ppm) por dois anos aumentou a incidência de papilomas e carcinomas de bexiga urinária em machos e fêmeas da linhagem Wistar; além disso, os ratos machos também apresentaram tendência a aumento do desenvolvimento de papilomas e carcinomas da pelve renal. Dois tumores renais, considerados raros para esta espécie, foram também observados em ratos Wistar machos expostos à maior concentração <sup>61</sup>. A deficiência neste estudo em ratos foi que vários órgãos não foram examinados, incluindo as glândulas mamárias.<sup>60</sup>

Camundongos NMR1 machos e fêmeas foram expostos a três concentrações de Diuron por 24 meses. As fêmeas expostas à maior

concentração de Diuron (2500 ppm) apresentaram tendência a aumento da incidência de adenocarcinomas de mama. Esta incidência foi considerada maior do que os dados de incidência histórica deste tipo de tumor em fêmeas controle em estudos com a mesma linhagem de camundongos.<sup>60,61</sup> Recentemente, em estudo epidemiológico realizado no estado da Califórnia, para avaliar a incidência de câncer de mama em mulheres que residiam em áreas próximas a regiões com grande uso de pesticidas, o Diuron foi incluído na lista de prováveis agentes cancerígeno para mama como um xenoestrógeno.<sup>62</sup>



## *Referências*

## 2. Referências

1. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA: a cancer journal for clinicians. 2005; Mar-Apr; 55(2):74-108.
2. Parkin DM, Pisani P, Ferlay J. Estimates of the worldwide incidence of 25 major cancers in 1990. Int J Cancer. 1999 Mar; 15; 80(6):827-41.
3. Jemal A, Thomas A, Murray T, Thun M. Cancer statistics, 2002. CA: a cancer journal for clinicians. 2002; Jan-Feb; 52(1):23-47.
4. Schultz LB, Weber BL. Recent advances in breast cancer biology. Current opinion in oncology. 1999; Nov; 11(6):429-34.
5. Domchek SM, Weber BL. Recent advances in breast cancer biology. Current opinion in oncology. 2002; Nov; 14(6):589-93.
6. Sorlie T, Perou CM, Tibshirani R, Aas T, Geisler S, Johnsen H, et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci U S A. 2001; Sep 11; 98(19):10869-74.
7. van 't Veer LJ, Dai H, van de Vijver MJ, He YD, Hart AA, Mao M, et al. Gene expression profiling predicts clinical outcome of breast cancer. Nature. 2002; Jan 31; 415(6871):530-6.
8. American Cancer Society. Surveillance Research, 2002.

9. Wolff MS, Weston A. Breast cancer risk and environmental exposures. *Environmental health perspectives*. 1997; Jun; 105 Suppl 4:891-6.
10. Snedeker SM. Pesticides and breast cancer risk: a review of DDT, DDE, and dieldrin. *Environmental health perspectives*. 2001; Mar; 109 Suppl 1:35-47.
11. Dewailly E, Dodin S, Verreault R, Ayotte P, Sauve L, Morin J, et al. High organochlorine body burden in women with estrogen receptor-positive breast cancer. *Journal of the National Cancer Institute*. 1994; Feb 2; 86(3):232-4.
12. Romieu I, Hernandez-Avila M, Lazcano-Ponce E, Weber JP, Dewailly E. Breast cancer, lactation history, and serum organochlorines. *American journal of epidemiology*. 2000; Aug 15; 152(4):363-70.
13. Perera FP. Environment and cancer: who are susceptible? *Science* (New York, NY. 1997; Nov 7; 278(5340):1068-73.
14. Anderson EL. Cancer risk assessments: an overview. In: *Oncogene and transgenic correlates of cancer risk assessments*. (Zervos C, ed). New York: Plenum Press. 1992; 1 – 20.
15. Russo J, Russo IH. Experimentally induced mammary tumors in rats. *Breast cancer research and treatment*. 1996; 39(1):7-20.

16. Medina D, Shepherd F. Selenium-mediated inhibition of 7,12-dimethylbenz[a]anthracene-induced mouse mammary tumorigenesis. *Carcinogenesis*. 1981; 2(5):451-5.
17. Grubbs CJ, Farnell DR, Hill DL, McDonough KC. Chemoprevention of N-nitroso-N-methylurea-induced mammary cancers by pretreatment with 17 beta-estradiol and progesterone. *Journal of the National Cancer Institute*. 1985; Apr; 74(4):927-31.
18. Welsch CW. Rodent models to examine in vivo hormonal regulation of mammary gland tumorigenesis. In: *Cellular and molecular biology of mammary cancer* (Medina D, Kidwell W, Heppner G, Anderson E, eds). New York: Plenum Press. 1987; 163 – 179.
19. Tornqvist M, Ehrenberg L. On cancer risk estimation of urban air pollution. *Environmental health perspectives*. 1994; Oct;102 Suppl 4:173-82.
20. Russo J, Wilgus G, Tait L, Russo IH. Influence of age and parity on the susceptibility of rat mammary gland epithelial cells in primary cultures to 7,12-dimethylbenz(a)anthracene. *In Vitro*. 1981; Oct; 17(10):877-84.
21. Russo I.H., Medado, J., Russo, J. Endocrine influence on mammary structure and development. In: *Integument and mammary gland of*

- laboratory animals (Jones, T.C., Mohr, U., Hunt, H. D, eds). Berlin: Springer-Verlag. 1989; 233 – 252,
22. Russo J & Russo, I.H., van Zwiete, M.J., Rogers, A.E. & Gusterson, B. Classification of neoplastic and nonneoplastic lesions of the rat mammary gland. In: Jone, T.C., Mohr, U. & Hunt, R.D., eds, Integument and Mammary Glands (Monographs on Pathology of Laboratory Animals, Berlin, Heidelberg, New York, Springer-Verlag. 1989b; pp. 233 - 252,
23. Russo J, Russo IH. Toward a physiological approach to breast cancer prevention. *Cancer Epidemiol Biomarkers Prev.* 1994; Jun; 3(4):353-64.
24. Gullino PM, Pettigrew HM, Grantham FH. N-nitrosomethylurea as mammary gland carcinogen in rats. *Journal of the National Cancer Institute.* 1975; Feb;54(2):401-14.
25. Dias MF, Sousa E, Cabrita S, Patricio J, Oliveira CF. Chemoprevention of DMBA-Induced Mammary Tumors in Rats by a Combined Regimen of Alpha-Tocopherol, Selenium, and Ascorbic Acid. *The breast journal.* 2000; Jan; 6(1):14-9.
26. Falck F, Jr., Ricci A, Jr., Wolff MS, Godbold J, Deckers P. Pesticides and polychlorinated biphenyl residues in human breast lipids and their

- relation to breast cancer. Archives of environmental health. 1992; Mar-Apr;47(2):143-6.
27. Wolff MS, Toniolo PG, Lee EW, Rivera M, Dubin N. Blood levels of organochlorine residues and risk of breast cancer. Journal of the National Cancer Institute. 1993 Apr 21;85(8):648-52.
28. Kniewald J, Jakominic M, Tomljenovic A, Simic B, Romac P, Vranesic D, et al. Disorders of male rat reproductive tract under the influence of atrazine. J Appl Toxicol. 2000; Jan-Feb; 20(1):61-8.
29. Stevens JT, Breckenridge CB, Wetzel LT, Gillis JH, Luempert LG, 3rd, Eldridge JC. Hypothesis for mammary tumorigenesis in Sprague-Dawley rats exposed to certain triazine herbicides. Journal of toxicology and environmental health. 1994; Oct; 43(2):139-53.
30. Eldridge JC, Fleenor-Heyser DG, Extrom PC, Wetzel LT, Breckenridge CB, Gillis JH, et al. Short-term effects of chlorotriazines on estrus in female Sprague-Dawley and Fischer 344 rats. Journal of toxicology and environmental health. 1994; Oct; 43(2):155-67.
31. Imagawa W, Bandyopadhyay GK, Nandi S. Regulation of mammary epithelial cell growth in mice and rats. Endocrine reviews. 1990; Nov; 11(4):494-523.

- 
32. Knight CH, Sorensen A. Windows in early mammary development: critical or not? *Reproduction* (Cambridge, England). 2001; Sep; 122(3):337-45.
33. Hovey RC, Trott JF, Vonderhaar BK. Establishing a framework for the functional mammary gland: from endocrinology to morphology. *Journal of mammary gland biology and neoplasia*. 2002; Jan; 7(1):17-38.
34. Brown NM, Manzillo PA, Zhang JX, Wang J, Lamartiniere CA. Prenatal TCDD and predisposition to mammary cancer in the rat. *Carcinogenesis*. 1998; Sep; 19(9):1623-9.
35. Lewis BC, Hudgins S, Lewis A, Schorr K, Sommer R, Peterson RE, et al. In utero and lactational treatment with 2,3,7,8-tetrachlorodibenzo-p-dioxin impairs mammary gland differentiation but does not block the response to exogenous estrogen in the postpubertal female rat. *Toxicol Sci*. 2001; Jul; 62(1):46-53.
36. Fenton SE, Hamm JT, Birnbaum LS, Youngblood GL. Persistent abnormalities in the rat mammary gland following gestational and lactational exposure to 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD). *Toxicol Sci*. 2002; May; 67(1):63-74.
37. Rayner JL, Wood C, Fenton SE. Exposure parameters necessary for delayed puberty and mammary gland development in Long-Evans rats

- exposed in utero to atrazine. *Toxicol Appl Pharmacol.* 2004; Feb 15; 195(1):23-34.
38. Rayner JL, Enoch RR, Fenton SE. Adverse effects of prenatal exposure to atrazine during a critical period of mammary gland growth. *Toxicol Sci.* 2005; Sep; 87(1):255-66
39. Ferrer A, Cabral R. Toxic epidemics caused by alimentary exposure to pesticides: a review. *Food additives and contaminants.* 1991; Nov-Dec; 8(6):755-75.
40. IARC Monographs on the Evaluation of Carcinogenic Risk to Humans. Occupational Exposures in Insecticide Application, and Some Pesticides. IARC Scientific Publications, Lyon.1991; Vol. 53.
41. Morrison HI, Wilkins K, Semenciw R, Mao Y, Wigle D. Herbicides and cancer. *Journal of the National Cancer Institute.* 1992; Dec 16; 84(24):1866-74.
42. Weisenburger D. Perspective in pathology: human health effects of agrichemical use, *Hum. Pathol.* 1993; 24: 571 – 576.
43. Compêndio de defensivos agrícolas: guia prático de produtos fitossanitários para uso agrícola. 6. ed. rev. Atual. São Paulo. Organização Andrei. 1999; p. 672.

- 
44. Spencer E.Y. Guide to chemicals used in crop protection. 7<sup>th</sup> edition. Research Branch, Agriculture Canada, Ottawa, 1982.
45. Ashton F.M. Persistence and biodegradation of herbicides. In: Biodegradation of pesticides. F. Matsumura and C.R. Krishna Murti (eds.). Plenum Press, New York, NY 1982; p. 117.
46. Hayes W.J., J.R. Pesticides studied in man. Baltimore, Williams & Wilkins, 1982. Hodge H.C., Downs, W.L., Panner, B., Smith, D., Maynard, E., Clayton, J., Jr. And Rhodes, R. Oral toxicity and metabolism of Diuron in rats and dogs. Food Cosmet. Toxicol. 1967; 5: 513.
47. Schoket B, Vincze I. Induction of rat hepatic drug metabolizing enzymes by substituted urea herbicides. Acta Pharmacol Toxicol (Copenh). 1985; Apr; 56(4):283-8.
48. Boyd EM, Krupa V. Protein-deficient diet and diuron toxicity. Journal of agricultural and food chemistry. 1970; Nov-Dec; 18(6):1104-7.
49. Worthing C.S. The pesticide manual, British Crop Protection Council, Lavenham Press, Suffolk. 1993; 339.
50. Khera KS, Whalen C, Trivett G, Angers G. Teratogenicity studies on pesticidal formulations of dimethoate, diuron and lindane in rats.

- Bulletin of environmental contamination and toxicology. 1979; Jul; 22(4-5):522-9.
51. Antony M, Shukla Y, Mehrotra NK. Tumour initiatory activity of a herbicide diuron on mouse skin. Cancer letters. 1989; Nov 30; 48(2):125-8.
52. Hodge HC, Downs WL, Panner BS, Smith DW, Maynard EA. Oral toxicity and metabolism of diuron (N-(3,4-dichlorophenyl)-N',N'-dimethylurea) in rats and dogs. Food and cosmetics toxicology. 1967; Oct; 5(4):513-31.
53. Grutman G, Schoofs L, Lontie JF, van Larebeke N. The mutagenicity in procaryotes of herbicides. Residue Rev. 1984; 91: 1-46.
54. Seiler JP. Herbicidal phenylalkylureas as possible mutagens I. Mutagenicity tests with some urea herbicides. Mutat Res. 1978; Nov; 58(2-3):353-9.
55. Dupont de Nemours & Co. Mutagenicity studies with Diuron. Salmonella test, No. HLR 471-84 (7185); CHO/HGPRT forward gene mutation assay, H.R. No. 282-85 06/28/85); unscheduled DNA synthesis test in primary rat hepatocytes, HLR No. 349-85; and in vivo cytogenetic test. 1985; No. 36685.

- 
56. Agrawal RC, Kumar S, Mehrotra NK. Micronucleus induction by diuron in mouse bone marrow. *Toxicology letters*. 1996; Dec; 89(1):1-4.
  57. Agrawal RC, Mehrotra NK. Effect of diuron on germ cells of mice. *Indian J Exp Biol*. 1997; Nov; 35(11):1256-7.
  58. U.S. Environmental Protection Agency (EPA). Diuron health advisory. Office of Drinking Water. 1987.
  59. IARC Monographs on the Evaluation of Carcinogenic Risk to Humans. Occupational Exposures in Insecticide Application, and Some Pesticides. IARC Scientific Publications, Lyon. 1991; Vol. 53.
  60. U.S Environmental Protection Agency (EPA). Increased incidence of malignant and combined malignant and benign tumors in male and female rats and increased incidence of malignant tumors in female mice. 1997.
  61. Bayer Institute of Toxicology. Diuron: Study for chronic toxicity and carcinogenicity with Wistar rats (administration in the diet for up to two years). Wuppertal: Bayer Institute of Toxicology; 1985. (DPR # 106-035).
  62. Reynolds P, Hurley SE, Gunier RB, Yerabati S, Quach T, Hertz A. Residential proximity to agricultural pesticide use and incidence of

breast cancer in California, 1988-1997. Environmental health perspectives. 2005; Aug; 113(8):993-1000.



## *Objetivos*

### **3. Objetivos**

Em decorrência dos poucos dados de literatura sobre a carcinogenicidade do herbicida Diuron e das informações da USEPA que apontam possíveis efeitos cancerígenos, em especial para a mama e bexiga em roedores, o presente projeto teve como objetivo geral avaliar o potencial carcinogênico do herbicida Diuron em modelo de carcinogênese mamária induzida pela 7,12-dimetilbenz(a)antraceno (DMBA) em fêmeas Sprague-Dawley (SD).

#### **3.1. Objetivos Específicos**

##### ***3.1.1. Protocolo Experimental I***

Avaliar se a exposição precoce (exposição em fase gestacional, lactacional e juvenil) ao herbicida Diuron, interfere no desenvolvimento/função do sistema reprodutivo e da glândula mamária na fase de pré-puberdade e/ou altera a susceptibilidade ao desenvolvimento da carcinogênese mamária induzida pela DMBA em fêmeas SD adulta.

##### ***3.1.2. Protocolo Experimental II***

Avaliar os possíveis efeitos do herbicida Diuron nos estágios de promoção e progressão da carcinogênese mamária induzida pela DMBA em fêmeas SD e os efeitos na expressão de biomarcadores da tumorigênese mamária (proliferação celular, apoptose, célula mioepitelial e receptor de estrógeno).



*Capítulo II*  
*Artigo Científico I*

## Evaluation of carcinogenic potential of Diuron in a rat mammary two-stage carcinogenesis model

Tony Fernando Grassi<sup>1</sup>, Maria Aparecida Marchesan Rodrigues<sup>1</sup>, João Lauro Viana de Camargo<sup>1</sup>, Luís Fernando Barbisan<sup>2\*</sup>

<sup>1</sup>Medical School, UNESP - São Paulo State University, Department of Pathology, Botucatu-SP, Brazil

<sup>2</sup>Institute of Biosciences, UNESP - São Paulo State University, Department of Morphology, Botucatu-SP, Brazil

*\*Address correspondence to:*

Luís Fernando Barbisan, Ph.D.

Departamento de Morfologia, Instituto de Biociências, Universidade Estadual Paulista (UNESP), Botucatu, 18618-000, SP, Brasil.

Telephone/Fax: 55-14-38116264

E-mail: [barbisan@ibb.unesp.br](mailto:barbisan@ibb.unesp.br)

*\*Artigo Científico de acordo com as normas da revista Toxicology and Applied Pharmacology (ISSN: 0041-008X)*

**Abstract**

This study aimed to evaluate the carcinogenic potential of the herbicide Diuron in a two-stage rat medium-term mammary carcinogenesis model initiated by 7,12-dimethylbenz(a)anthracene (DMBA). Female seven week old Sprague-Dawley (SD) rats were allocated to six groups: Groups G1 to G4 received intragastrically (i.g.) a single 50 mg/kg dose of DMBA; Groups G5 and G6 received only a single administration of Canola oil (vehicle of DMBA). Groups G1 and G5 received a basal diet, and Groups G2, G3, G4 and G6 the basal diet added with Diuron at 250, 1250, 2500 and 2500 ppm, respectively. After 25 weeks, the animals were euthanized and mammary tumors were confirmed histologically and quantified. Tumor samples were also processed for immunohistochemical evaluation of the expressions of proliferating cell nuclear antigen (PCNA), caspase-3, estrogen-receptor-alpha (ER-alpha), p63, bcl-2 and bak. Diuron did not increase the incidence or multiplicity of mammary tumors (Groups G2, G3 and G4 *vs.* Group G1). Also, exposure to Diuron did not alter tumor growth (cell proliferation and apoptosis rates) or immunoreactivity to ER-alpha, p63 (myoepithelial marker), bcl-2 and bak (apoptosis regulatory proteins). These findings indicate that Diuron does not have a promoting potential on mammary carcinogenesis in female SD rats initiated with DMBA.

**Key words:** pesticides, Diuron, mammary carcinogenesis, Sprague-Dawley rats

**Running title:** Diuron and rat mammary carcinogenesis

## 1. Introduction

Breast cancer is an invasive and ultimately fatal disease whose incidence in postmenopausal women has gradually increased in most Western societies over the last few decades. The incidences have also sharply increased in younger women in more recent years, mainly in industrialized countries (Parkin *et al.* 2005; Bouchardy *et al.* 2007).

Besides genetic/familial factors including the major susceptibility genes (BRCA1 and BRCA2), other influences on breast cancer risk appear to be certain reproductive factors (i.e., older age, later age at first full-term pregnancy, no full-term pregnancies), body size/obesity, alcohol, exogenous hormones (oral contraceptives, hormone replacement therapy), menopause and possibly, some dietary habits (Parkin *et al.* 2005; Bouchardy *et al.* 2007). In the early 1990s, it was suggested that exposure to some environmental chemicals such as pesticides could play a causal role in the etiology of breast cancer through estrogen-related pathways or endocrine disrupting effects. Substantial evidence from experimental rodent studies indicate that organochlorine pesticides are potential mammary carcinogens. In contrast, direct correlations between human tissue levels of pesticides and the development of breast cancer have not been consistent, with positive and negative associations (Calle *et al.* 2002; Fenton 2006; Rudel *et al.* 2007; Salehi *et al.* 2008).

Diuron [3-(3,4-dichlorophenyl)-1,1-dimethylurea] is a substituted phenyl urea herbicide used throughout the world to control a wide variety of annual and perennial broadleaf and grassy weeds on both crop (i.e., citrus fruit, cotton, asparagus, sugar cane, alfalfa, wheat and grapes) and non-crop sites (i.e., roads, garden paths and railways) (Iyer, 2002; Field *et al.* 2003; Giacomazzi and Cochet 2004). In Brazil, it is widely used on many agricultural crops such as sugar cane and soy (Nascimento *et al.* 2006). Diuron *per se* has low systemic toxicity to mammals and birds, and moderate toxicity to aquatic invertebrates. Its principal biodegradation product, 3,4-dichloroaniline (3-DCA), is highly toxic and relatively persistent in the environment (Valentovic *et al.* 1997; Iyer, 2002; Giacomazzi and Cochet 2004). Thus, the environmental contamination by this herbicide may represent an important public health problem (Abass *et al.* 2007; Sorensen *et al.* 2008).

In a recent epidemiological study in areas of high agricultural pesticides use, no association between Diuron exposure and breast cancer was observed in Californian women (Reynolds *et al.* 2005). However, for more than one decade Diuron has been categorized as a “known/likely” human carcinogen by the U. S. Environmental Protection Agency (USEPA) mostly based on long-term bioassays that indicated increased incidences of urothelial bladder and renal pelvis tumors after continuous dietary high concentration (2500 ppm) exposure in both genders of Wistar rats, and a trend for increased incidence of mammary adenocarcinomas in female NMRI mice (Iyer, 2002;

USEPA, 2003; 2004). In these long-term studies, the mammary glands of the Wistar female rats, a strain known to be resistant to chemically-induced breast tumors, seems to be not adequately examined, but, the NMR1 female mice developed increased although relatively low incidences of adenocarcinomas: 2/50, 1/47, 1/49 and 6/50 in female mice after exposed through diet to 0, 25, 250, and 2500 ppm of Diuron, respectively (Iyer, 2002). The 12% incidence of mammary tumors led the USEPA to assume that a positive oncogenic response was seen in the highest dose group when compared to the control, after discarding the possibility of those tumors being spontaneous (USEPA, 2003). While the carcinogenic mode of action of Diuron on the rat urothelia has been more intensively studied and seems to be by a non-genotoxic pathway (Nascimento *et al.*, 2006; Rocha *et al.*, 2009), the mammary carcinogenesis process referred to Diuron exposure has not been adequately explored.

The most widely used medium-term bioassay to assess the carcinogenic potential of chemicals on mammary carcinogenesis is based on the 7-12-dimethylbenz(a)anthracene (DMBA)-induced tumors in the highly susceptible female Sprague-Dawley rats, whose tumors closely mimic human breast cancer (Russo and Russo 1996; Costa *et al.* 2002). This *in vivo* bioassay is useful for dissecting the multistep process of carcinogenesis and for detection of potential mammary carcinogens, especially those that act through endocrine disruption (Russo and Russo 1996; Costa *et al.* 2002; Fenton 2006; Rudel *et al.*

2007). Thus, the identification of potential mode of action as well as possible species-specific response of laboratory rodents may assist in the selection and further development of appropriate models for assessing the evaluation of mammary carcinogenicity of Diuron.

As breast cancer is one of the most frequent neoplasm in women and hazard detection and risk assessments of environmental chemicals for breast cancer are high public health priorities, the present study was conducted to assess the modifying effects of the herbicide Diuron on the promotion/progression stages of mammary carcinogenesis induced by DMBA in virgin female Sprague-Dawley (SD) rats. In addition, effects of Diuron on cell proliferation and apoptosis were also examined.

## 2. Material and Methods

### 2.1. Chemicals

7,12-Dimethylbenz(a)anthracene (DMBA, CAS 57-97-6) and 3-(3,4-dichlorophenyl)-1,1-dimethylurea (Diuron, CAS 30-54-1, analytical standard grade) were purchased from Sigma-Aldrich Co., USA.

### 2.2. Experimental Design

The University Committee for Ethics in Animal Research approved the present study (Protocol number 523). Female 5-week-old Sprague-Dawley (SD) rats were obtained from the Multidisciplinary Center for Biological Investigation (CEMIB/UNICAMP, Campinas-SP, Brazil). They were kept in polypropylene cages (five animals/cage) with metallic grid covers, and maintained in a room at  $22\pm 2^{\circ}\text{C}$ ,  $55\pm 10\%$  humidity and a 12h light/dark cycle. They were fed commercial Purina chow (Paulínia, SP, Brazil) and water *ad libitum* during a 2-week acclimatization period.

The animals were randomly allocated to six groups, consisting of 18 rats in groups G1 to G4, 10 rats in group G5 and 15 rats in group G6. After two weeks of acclimatization, with seven weeks of age, groups G1 to G4 were initiated for mammary carcinogenesis by a single intragastric (i.g.) dose of 50 mg/kg body weight of DMBA; groups G5 and G6 received a single i.g. dose of Canola oil (DMBA vehicle, 1ml/kg). After one week, Groups G1 and G5 were kept in the commercial basal diet and Groups G2, G3, G4 and G6

received the same diet added with 250, 1250, 2500 or 2500 ppm of Diuron, respectively, for 25 weeks. During the experimental period, the animals were carefully checked once a week for the presence of gross mammary tumors; data on the number and localization of each palpable mass in the six mammary complexes were recorded. Sacrificed moribund rats and deceased animals were autopsied; those surviving for 23 or more weeks of Diuron treatment were included in the effective number of rats for histopathology and immunohistochemistry analysis. All animals were euthanatized by exsanguination under sodium pentobarbital anesthesia (45 mg/kg b.w.). Individual body weights and food consumption were recorded weekly during the experimental period.

### **2.3. Hormone analysis and tissue processing for histology**

Immediately before sacrifice, samples of peripheral blood were collected for estrogen and progesterone plasma determinations. Estrogen and progesterone levels were determined automatically (VITROS ECI-Johnson and Johnson Ultra-Sensitive Chemiluminescence analysis, USA) using specific reagents supplied by Johnson and Johnson Orthoclinical (São Paulo-SP, Brazil). At necropsy, the whole skin with mammary glands and tumors, liver, kidneys, spleen, ovaries, uterus and vagina were removed and fixed for 24h in 10% phosphate-buffered formalin. Before fixation, mammary tumors, liver, kidneys, spleen, ovaries and uterus were weighed. Samples of organs/tissues

were processed in order to provide 5 µm thick paraffin sections for histological (hematoxylin-eosin – H&E) and immunohistochemical analysis.

Proliferative or neoplastic lesions in mammary glands and in reproductive system (i.e., oviduct, ovary, uterus, cervix and vagina) were classified according to published criteria by The Society of Toxicologic Pathology (SSNDC Guides, 2006).

#### **2.4. PCNA, caspase-3, p63, RE, bcl-2 and bak immunostaining**

Histological sections were put on poly-l-lysine coated slides, deparaffinized and rehydrated with graded alcohol. Sections were subjected to microwave antigen retrieval in citric acid buffer at pH 6.0 for 3 x 5 min (PCNA, caspase-3, p63, bcl-2 and bak primary antibodies) or Pascal pressure chamber retrieval in citrate acid buffer at pH 6.0 at 120°C for 3 min (estrogen receptor-alpha antibody). Endogenous peroxidase was blocked with 3% H<sub>2</sub>O<sub>2</sub> in phosphate-buffered saline (PBS) for 10 min in dark. After washing with PBS, slides were incubated with non-fat milk in PBS for 60 min. Sections were then incubated with primary antibodies mouse monoclonal anti-PCNA/PC10 (1:200 dilution) (DakoCytomation Denmark A/S, Glostrup, Denmark), rabbit polyclonal anti-caspase-3 cleaved /Asp 175 rabbit (1:100 dilution) (Cell Signaling Technology Inc., Danvers, MA - USA), mouse monoclonal anti-ER-alpha/6F11 (1:50 dilution) (BioCare Medical – Concord, CA – USA), monoclonal mouse anti-p63/4A4 (1:100 dilution) (Dako Cytomation

Denmark A/S) and anti-polyclonal rabbit anti-bcl2/N-19 (1:200 dilution) and polyclonal rabbit anti-bak/G-23 (1:200 dilution) (Santa Cruz Biotechnology Inc., CA - USA) for overnight. This was followed by biotinylated secondary antibodies horse anti-mouse or goat anti-rabbit (Vector Laboratories Inc., Burlingame, CA, USA) for 60 min and incubated with streptavidin-biotin complex/horseradish peroxidase (Vector Laboratories Inc.), both at room temperature. Chromogen color development was accomplished with 3,3'-diaminobenzidine tetrahydrochloride (DAB, Sigma-Aldrich Co.) as the substrate to demonstrate the sites of peroxidase binding. The slides were counterstained with Harris's hematoxylin. A negative control was performed in all cases by omitting incubation with the primary antibodies for PCNA, caspase-3, ER-alpha, p63, bcl-2 and bak, which in all instances resulted in negative immunoreactivity.

The rates of PCNA S-phase, and of caspase-3 cleaved labeling and of apoptosis (HE staining) in mammary tumor sections were calculated as the number of positively marked cells divided by the total number of cells scored x 100 (10 representative microscopic fields without necrosis with ~ 10,000 tumor cells in each tumor section). The immunoreactivities for p63, ER-alpha, bcl-2 and bak were evaluated using a score system. The score is based on estimating both the percentage of positively stained cells on a slide (proportion score) and the general strength of the staining (intensity score). The proportion score is ranked as 0 for negative; 1 for < 10%, 2 for >10%

and  $< 50\%$  or 3 for  $> 50\%$  of cells stained. The intensity score is ranked as 1 for weak, 2 for moderate or 3 for strong expression. The combined score was represented by multiplication product of the proportion score and the intensity score (Ip *et al.* 2000).

## 2.5. Statistical Analysis

Data for body weight and body-weight gain, food consumption, relative liver kidney, spleen weights, tumor weights, estrogen and progesterone plasma levels were analyzed by ANOVA when the results presenting normal distribution or Kruskal-Wallis test when this did not occur. Analyses of the semi-quantitative combined scores were performed using the Kruskal-Wallis test. Contrast among groups was analyzed by the Tukey or Student-Newman-Keuls methods. Incidences of mammary tumor were examined using the chi-squared or the Fischer test. Significant differences were assumed when  $P < 0.05$ . The statistical analyses were performed using the Jandel Sigma Stat software (Jandel Corporation, San Rafael, CA, USA).

### 3. Results

#### 3.1. Mortality, body and organ weights, food consumption and hormonal analysis

At the end of the experimental period, survival rates were 72.2% in DMBA-initiated group (G1, n= 13), 77.8%, 88.9% and 83.3% in DMBA-initiated and Diuron-treated groups to 250 (G2, n= 14), 1250 (G3, n= 16) and 2500 ppm (G4, n= 15) respectively, and survival rates were 100% in both non-initiated groups (G5, n= 10 and G6, n = 15, respectively) (Table 1).

During Diuron treatment, food consumption and body-weight gain (Figure 1) were significantly reduced ( $P < 0.001$ ) in DMBA-initiated/Diuron-treated 1250 and 2500 ppm and non-initiated/Diuron-treated 2500 ppm groups (G3, G4 and G6, respectively) when compared to the respective control groups (Table 1). At week 25, DMBA-initiated/Diuron-treated 2500 ppm and non-initiated/Diuron-treated 2500 ppm groups (G4 and G6, respectively) had lower final body weights ( $P < 0.001$ ) than their respective control groups (Table 1). Increased relative liver and spleen weights ( $P < 0.001$ ) were observed in DMBA-initiated/Diuron-treated 1250 and 2500 ppm groups (G3 and G4) and in non-initiated and Diuron-treated 2500 ppm (G6) (Table 2). Increased relative right and left kidney weights ( $P = 0.026$ ;  $P = 0.006$ , respectively) and decreased relative left ovary weight ( $P = 0.004$ ) were observed in non-initiated and Diuron-treated 2500 ppm group (G6) when compared to the non-initiated group (G5) (Table 2).

Diuron treatment did not cause any significant alterations in estrogen (pg/ml) or progesterone (ng/ml) plasma levels when compared to the respective controls (Table 3).

### 3.2. Histopathologic and immunohistochemical analysis

Sixty mammary tumors were histologically confirmed in DMBA-initiated groups. The majority of them was classified as adenocarcinomas with either tubular, papillary or comedo-cribriform patterns or mixed structures (57/60); the others were adenomas (2/60) and fibroma (1/60) (Table 3). The prevailing histological tumor pattern was considered for classification. In general, adenocarcinomas induced by DMBA presented an expansive pattern with local invasive areas. In non-initiated/Diuron treated 2500 ppm animals (G6) no hyperplastic lesion (lobular or atypical) or benign or malignant neoplasms were observed in the mammary glands.

Treatment with Diuron did not alter the latency period (i.e., time to first palpable mammary tumor), incidence, multiplicity, tumor weights and histological patterns in female SD rats initiated with DMBA (Table 3). Also, malignant mammary neoplasms were further characterized by a number of immunohistochemical markers such as PCNA, caspase-3 cleaved, p63 (myoepithelial marker), bcl-2 and bak (apoptosis regulatory proteins) and ER-alpha (Figure 2A-F). As the rates of caspase-3 cleaved positive apoptotic cells correlated well with the corresponding rates of H&E stained apoptotic cells

(Figure 2B1), the apoptosis indexes (AI%) were estimated in both caspase-3 cleaved expression and morphological aspects (H&E stained sections) (Eckle *et al.* 2004).

The different Diuron dietary levels did not change the indexes of cell proliferation (PCNA LI%) and apoptosis (AI%) in mammary tumors. Immunoreactivity for p63 nuclear protein and for apoptosis regulatory proteins bcl-2 and bak and ER-alpha were variably expressed in different regions of the tumor (central, periphery, or in proliferating or necrotic areas), irrespective of their histological patterns. The semi-quantitative combined score system herein adopted indicated that the treatment with Diuron also did not change the patterns of immunoexpression of p63, bcl-2, bak or ER-alpha in the DMBA-induced neoplasms (Table 4).

Some female SD rats exposed to Diuron 2500 ppm (groups G4 and G6) developed liver centrilobular hypertrophy, splenomegaly and urothelial hyperplasia in the urinary bladder and renal pelvis. These changes were related to the influence of high concentrations of Diuron since they have been already reported in previous studies (Nascimento *et al.* 2006; Grassi *et al.* 2007; Fernandes *et al.* 2007).

#### 4. Discussion

The results of the present study indicate that a 25-week long exposure to high dietary concentrations of Diuron does not modify the mammary carcinogenesis process initiated by DMBA in the highly susceptible female SD rats. Also, different Diuron exposure levels did not alter the histological patterns, the rates of cell proliferation and apoptosis, and the immunoreactivity of ER-alpha, p63, bcl-2 and bak biomarkers in developing tumors. These findings were obtained using a dietary concentration of Diuron reported to be carcinogenic to the urinary bladder male and female Wistar rats and to the mammary gland of female NMRI mice in long-term feeding studies (Iyer, 2002); (USEPA, 2003).

The oral exposure to Diuron at 2500 ppm for 25-week also did not initiate the mammary carcinogenesis process since no preneoplastic or neoplastic lesion were histologically detected in the mammary glands of non-initiated female SD rats. It is not surprising that Diuron alone did not initiate the carcinogenesis process in this organ. Although some reports in the literature suggest that Diuron is genotoxic (Agrawal *et al.* 1996; Agrawal and Mehrota 1997; Bouilly *et al.* 2007), studies developed in our laboratory indicated that the herbicide does not damage DNA *in vivo* (Nascimento *et al.* 2006) and does not induce *crosslinks in vitro* (Rocha *et al.*, 2009) when tested by the comet (single cell gel eletrophoresis) assay. Besides, Diuron did not exert initiating or promoting potentials in the skin of Swiss albino mice (Ferrucio *et*

*al.*, 2009). These observations are in line with others reported in the literature stating that diuron is a non-genotoxic agent (Liu, 2001; Iyer, 2002; USEPA, 2003).

In the present study, oral exposure to Diuron did not exert any promoting effect on the mammary carcinogenesis process initiated by DMBA when latency, incidence, multiplicity and histological patterns were used as parameters. In fact, although not significantly, fewer tumors (tumor burden) were observed in DMBA-initiated groups fed higher dietary levels of Diuron (1250 and 2500 ppm). This finding could be directly associated to the reduction of body weight gain (-15 % and -33%, respectively) and food consumption (-4% and -13%, respectively) observed in these two groups at the end of the experiment (Table 1). Chemical treatments that decrease body weight gain associated with toxicity, to non-palatability, or to indirect food restriction are likely to inhibit the development of rodent mammary tumors in medium- and in long-term bioassays (Rudel *et al.* 2007).

Cell proliferation and apoptosis play an important role during the progression of the rat mammary gland tumorigenesis (Strange *et al.* 2001; Al-Dhaheri *et al.* 2008). PCNA, a co-factor for delta-DNA-polymerase leading to DNA replication and DNA-damage repair, has been considered a feasible marker for cell proliferation in mammary carcinogenesis (Al-Dhaheri *et al.* 2008). Bcl-2 family members are pivotal in the regulatory processes that either repress (e.g., bcl-2 and bcl-x1) or induce (e.g., bak, bax, and bad) apoptosis

(Kuwana and Newmeyer, 2003; Brunelle and Letai, 2009). In premalignant lesions and during mammary tumor progression in the female rat, increases in cell proliferation and imbalances of the anti-apoptotic bcl-2 and bcl-x and pro-apoptotic bax or bak proteins have been described (Xie *et al.* 1999; Shilkaitis *et al.* 2000; Strange *et al.* 2001; Al-Dhaheri *et al.* 2008). However, in the present study Diuron did not alter significantly cell proliferation or apoptosis indexes or the expressions of bcl-2 and bak proteins in the DMBA-initiated mammary tumors.

p63 is a p53-related DNA-binding protein that has been described as a nuclear transcriptional factor involved with differentiation, maintenance and proliferation of epithelial progenitor cells (stem cells) (Barbieri and Pietenpol, 2006). This myoepithelial cell marker has been observed in normal and neoplastic tumors of both human and rat mammary tissues (Ribeiro-Silva *et al.*, 2005; Chan *et al.*, 2005; Rakha *et al.*, 2006). In human breast cancer, p63 has been shown to be expressed in *in situ* ductal carcinoma and in benign neoplasms, but is frequently absent in invasive lesions (Ribeiro-Silva *et al.*, 2005; Rakha *et al.*, 2006). In this study, p63 immunoreactivity was observed in basal cells of most neoplastic ducts-like structures or in focal areas not directly lining epithelial mammary neoplastic cells. Thus, mammary tumors induced by DMBA in SD female rats can be constituted by a mixed cellular lineage (i.e., epithelial and myoepithelial cells) as previously described for mammary

neoplasms induced by MNU (Chan *et al.*, 2005) and this structural pattern was not altered by exposure to Diuron.

Some pesticides with potential endocrine disrupting properties have been categorized as mammary carcinogens in rodent studies (Rudel *et al.* 2007; Ueda *et al.* 2005). These pesticides, including some substituted urea herbicides, are able to block or inactivate the steroid hormone receptors and/or affect the levels of pituitary hormones with potential to alter the development and function of the male and female reproductive systems (Bauer *et al.* 1998; Cook *et al.* 1993; Vinggaard *et al.* 1999; 2000; Kojima *et al.* 2004; Noguerol *et al.* 2006). *In vitro* assays indicate that Diuron did not inhibit 5 $\alpha$ -reductase activity but has the capability to connect to the androgen receptor, thus acting as a male endocrine disruptor (Bauer *et al.* 1998). Also, Diuron did show estrogen receptor (ER)-mediated response in human MCF-7 breast cancer cells, Chinese hamster ovary cells or recombinant yeast strains (Vinggaard *et al.* 1999; Kojima *et al.* 2004; Noguerol *et al.* 2006). However, Diuron did not affect CYP19 aromatase activity in the human placental microsomes assay, indicating that it does not interfere with the conversion of androgens to estrogens, which could alter the balance between male and female sex hormones (Vinggaard *et al.* 2000). The present findings showing absence of promoting effects of Diuron on mammary carcinogenesis are in agreement with these *in vitro* assay negative results.

Estrogens have important physiological effects on the growth and function of hormone-dependent tissues, including the mammary gland but its are also associated with the development and progression of breast cancer (Matthews and Gustafsson, 2003; Petterson and Gustafsson, 2001; Couse and Korach, 1999). Estrogens exert their carcinogenic effects by both estrogen receptors (ER)-dependent and ER-independent pathways. In special, the ER-dependent pathway involves the activation of the ER by estrogens, leading to the expression of estrogen responsive genes, as well as stimulation of cell growth and proliferation (Khan *et al.*, 1998). The ER-alpha is a ligand dependent transcription factor that regulates a large number of genes in many different target tissues and is important in the development and progression of estrogen-responsive neoplastic cells (DeSombre, 2000). In the present study, the positive expression rate of ER-alpha was approximately 80 % in a total of 60 tumors. In fact, as most mammary tumors induced by DMBA are estrogen-(ER) positive and dependent of hormonal status (Russo and Russo, 1996), our results also indicate that the rat mammary gland is not a potential target for the carcinogenic potential of Diuron since the serum estradiol levels, tumor burden and the immunoexpression of ER-alpha in the tumors were not altered.

Finally, no histological evidences of Diuron toxicity on reproductive organs like ovary, uterus and vagina were observed in this study. This is at difference with the herbicide atrazine which has been categorized as endocrine

disruptor and a potential mammary carcinogen for female SD in chronic feeding studies. In high-doses, atrazine has been related to an acceleration of age-related endocrine changes leading to an earlier onset and/or increased incidence of chemically-induced mammary tumors in females SD rats. This sex/strain endocrine-mediated response, which appears to be unique to the SD female rat, occurs only at high doses that interfere with normal estrous cycling, promoting prolonged exposure to endogenous estrogen and prolactin (Wetzel *et al.*, 1994; Stevens *et al.*, 1999). Therefore, the present results suggest that Diuron also does not have a female endocrine disruptor potential like the herbicide atrazine.

Since in the present study no initiating or promoting influences of Diuron on the chemically-induced mammary gland carcinogenesis process were registered in female SD rats, it can be assumed that the rat mammary glands are not potential targets for the toxicity of this herbicide. Studies designed to understand the mode of action of high dose of Diuron on the mammary gland of female NRMI mice, as reported by others (Iyer, 2002), may lead to better understanding of the possible species-specific mammary carcinogenic activity of this herbicide and its potential relevance to humans.

---

## 5. Acknowledgments

This study was supported by FAPESP (State of São Paulo Research Foundation) and TOXICAM (Centre of the Evaluation of the Impact of the Environment on Human Health, Department of Pathology - Botucatu Medical School, UNESP, Brazil). Grassi, T.F. was recipient of a fellowship from FAPESP (2006/01330-0).

---

## 6. References

Abass, K., Reponen, P., Turpeinen, M., Jalonen, J., and Pelkonen, O., 2007. Characterization of diuron N-demethylation by mammalian hepatic microsomes and cDNA-expressed human cytochrome P450 enzymes. *Drug Metab Dispos* 35, 1634-41.

Agrawal, R. C., Kumar, S., and Mehrotra, N. K., 1996. Micronucleus induction by diuron in mouse bone marrow. *Toxicology letters* 89, 1-4.

Agrawal, R. C., and Mehrotra, N. K., 1997. Effect of diuron on germ cells of mice. *Indian J Exp Biol* 35, 1256-7.

Al-Dhaheer, W. S., Hassouna, I., Al-Salam, S., and Karam, S. M., 2008. Characterization of breast cancer progression in the rat. *Ann N Y Acad Sci* 1138, 121-31.

Barbieri, C. E., and Pietenpol, J. A., 2006. p63 and epithelial biology. *Exp Cell Res* 312, 695-706.

Bauer, E. R., Meyer, H. H., Stahlschmidt-Allner, P., and Sauerwein, H., 1998. Application of an androgen receptor assay for the characterisation of the androgenic or antiandrogenic activity of various phenylurea herbicides and their derivatives. *Analyst* 123, 2485-7.

---

Bouchardy, C., Fioretta, G., Verkooijen, H. M., Vlastos, G., Schaefer, P., Delaloye, J. F., Neyroud-Caspar, I., Balmer Majno, S., Wespi, Y., Forni, M., Chappuis, P., Sappino, A. P., and Rapiti, E., 2007. Recent increase of breast cancer incidence among women under the age of forty. *British journal of cancer* 96, 1743-6.

Bouilly, K., Bonnard, M., Gagnaire, B., Renault, T., and Lapegue, S., 2007. Impact of diuron on aneuploidy and hemocyte parameters in Pacific oyster, *Crassostrea gigas*. *Arch Environ Contam Toxicol* 52, 58-63.

Brunelle, J. K., and Letai, A., 2009. Control of mitochondrial apoptosis by the Bcl-2 family. *J Cell Sci* 122, 437-41.

Calle, E. E., Frumkin, H., Henley, S. J., Savitz, D. A., and Thun, M. J., 2002. Organochlorines and breast cancer risk. *CA: a cancer journal for clinicians* 52, 301-9.

Chan, M. M., Lu, X., Merchant, F. M., Iglehart, J. D., and Miron, P. L., 2005. Gene expression profiling of NMU-induced rat mammary tumors: cross species comparison with human breast cancer. *Carcinogenesis* 26, 1343-53.

---

Cook, J. C., Mullin, L. S., Frame, S. R., and Biegel, L. B., 1993. Investigation of a mechanism for Leydig cell tumorigenesis by linuron in rats. *Toxicol Appl Pharmacol* 119, 195-204.

Costa, I., Solanas, M., and Escrich, E., 2002. Histopathologic characterization of mammary neoplastic lesions induced with 7,12 dimethylbenz(alpha)anthracene in the rat: a comparative analysis with human breast tumors. *Archives of pathology & laboratory medicine* 126, 915-27.

Eckle, V. S., Buchmann, A., Bursch, W., Schulte-Hermann, R., and Schwarz, M., 2004. Immunohistochemical detection of activated caspases in apoptotic hepatocytes in rat liver. *Toxicol Pathol* 32, 9-15.

Fenton, S. E., 2006. Endocrine-disrupting compounds and mammary gland development: early exposure and later life consequences. *Endocrinology* 147, S18-24.

Fernandes, G. S., Arena, A. C., Fernandez, C. D., Mercadante, A., Barbisan, L. F., and Kempinas, W. G., 2007. Reproductive effects in male rats exposed to diuron. *Reprod Toxicol* 23, 106-12.

Ferrucio, B., Franchi, C.A., de Oliveira, M.L.C. de Oliveira, D. E., de Camargo, J.L.V., 2009. Diuron and mice skin carcinogenesis. *Society of*

---

Toxicologic Pathology. 28th Annual Symposium, Washington, DC, P-5 (Abstract).

Field, J. A., Reed, R. L., Sawyer, T. E., Griffith, S. M., and Wigington, P. J., Jr., 2003. Diuron occurrence and distribution in soil and surface and ground water associated with grass seed production. *Journal of environmental quality* 32, 171-9.

Giacomazzi, S., and Cochet, N., 2004. Environmental impact of diuron transformation: a review. *Chemosphere* 56, 1021-32.

Grassi, T. F., Tararam, C. A., Spinardi-Barbisan, A. L., Domingues, M. A., de Camargo, J. L., and Barbisan, L. F., 2007. Diuron lacks promoting potential in a rat liver bioassay. *Toxicol Pathol* 35, 897-903.

Ip, C., Ip, M. M., Loftus, T., Shoemaker, S., and Shea-Eaton, W., 2000. Induction of apoptosis by conjugated linoleic acid in cultured mammary tumor cells and premalignant lesions of the rat mammary gland. *Cancer Epidemiol Biomarkers Prev* 9, 689-96.

Iyer, P., 2002. Evidence on the development and reproductive toxicity of Diuron draft. Reproductive and cancer hazard assessment section. Office of

---

Environmental Health Hazard Assessment, California Environmental Protection Agency, p. 43

Kojima, H., Katsura, E., Takeuchi, S., Niiyama, K., and Kobayashi, K., 2004. Screening for estrogen and androgen receptor activities in 200 pesticides by in vitro reporter gene assays using Chinese hamster ovary cells. *Environmental health perspectives* 112, 524-31.

Kuwana, T., and Newmeyer, D. D., 2003. Bcl-2-family proteins and the role of mitochondria in apoptosis. *Curr Opin Cell Biol* 15, 691-9.

Liu, J., 2001. Phenylurea herbicides. In: Krieger, K.E. (Ed.), *Handbook of Pesticides Toxicology—Agents*. Academic Press, San Diego, pp. 1521–1523.

Nascimento, M. G., de Oliveira, M. L., Lima, A. S., and de Camargo, J. L., 2006. Effects of Diuron [3-(3,4-dichlorophenyl)-1,1-dimethylurea] on the urinary bladder of male Wistar rats. *Toxicology* 224, 66-73.

Noguerol, T. N., Boronat, S., Casado, M., Raldua, D., Barcelo, D., and Pina, B., 2006. Evaluating the interactions of vertebrate receptors with persistent pollutants and antifouling pesticides using recombinant yeast assays. *Analytical and bioanalytical chemistry* 385, 1012-9.

- Parkin, D. M., Bray, F., Ferlay, J., and Pisani, P., 2005. Global cancer statistics, 2002. *CA: a cancer journal for clinicians* 55, 74-108.
- Rakha, E. A., Putti, T. C., Abd El-Rehim, D. M., Paish, C., Green, A. R., Powe, D. G., Lee, A. H., Robertson, J. F., and Ellis, I. O., 2006. Morphological and immunophenotypic analysis of breast carcinomas with basal and myoepithelial differentiation. *J Pathol* 208, 495-506.
- Reynolds, P., Hurley, S. E., Gunier, R. B., Yerabati, S., Quach, T., and Hertz, A., 2005. Residential proximity to agricultural pesticide use and incidence of breast cancer in California, 1988-1997. *Environmental health perspectives* 113, 993-1000.
- Ribeiro-Silva, A., Ramalho, L. N., Garcia, S. B., Brandao, D. F., Chahud, F., and Zucoloto, S., 2005. p63 correlates with both BRCA1 and cytokeratin 5 in invasive breast carcinomas: further evidence for the pathogenesis of the basal phenotype of breast cancer. *Histopathology* 47, 458-66.
- Rocha, M. S., Nascimento, M. G., Cardoso, A. P. F., Alves de Lima, P. L., Zelandi, E. A., de Camargo, J. L. V. Oliveira, M. L. C. S., 2009. Cytotoxicity and regenerative proliferation as the mode of action for Diuron-induced urothelial carcinogenesis in the rat. *Toxicological Sciences*, doi:10.1093/toxsci/kfp241.

---

Rudel, R. A., Attfield, K. R., Schifano, J. N., and Brody, J. G., 2007. Chemicals causing mammary gland tumors in animals signal new directions for epidemiology, chemicals testing, and risk assessment for breast cancer prevention. *Cancer* 109, 2635-66.

Russo, J., and Russo, I. H., 1996. Experimentally induced mammary tumors in rats. *Breast cancer research and treatment* 39, 7-20.

Salehi, F., Turner, M. C., Phillips, K. P., Wigle, D. T., Krewski, D., and Aronson, K. J., 2008. Review of the etiology of breast cancer with special attention to organochlorines as potential endocrine disruptors. *J Toxicol Environ Health B Crit Rev* 11, 276-300.

Shilkaitis, A., Green, A., Steele, V., Lubet, R., Kelloff, G., and Christov, K., 2000. Neoplastic transformation of mammary epithelial cells in rats is associated with decreased apoptotic cell death. *Carcinogenesis* 21, 227-33.

Sorensen, S. R., Albers, C. N., and Aamand, J., 2008. Rapid mineralization of the phenylurea herbicide diuron by *Variovorax* sp. strain SRS16 in pure culture and within a two-member consortium. *Appl Environ Microbiol* 74, 2332-40.

---

Standardized System of Nomenclature and Diagnostic Criteria (SSNDC) Guides., 2006. Society of Toxicologic Pathology. [www.toxpath.org/ssndc.asp](http://www.toxpath.org/ssndc.asp).

Stevens, J. T., Breckenridge, C. B., and Wetzel, L., 1999. A risk characterization for atrazine: oncogenicity profile. *J Toxicol Environ Health A* 56, 69-109.

Strange, R., Metcalfe, T., Thackray, L., and Dang, M., 2001. Apoptosis in normal and neoplastic mammary gland development. *Microsc Res Tech* 52, 171-81.

Ueda, M., Imai, T., Takizawa, T., Onodera, H., Mitsumori, K., Matsui, T., and Hirose, M., 2005. Possible enhancing effects of atrazine on growth of 7,12-dimethylbenz(a) anthracene-induced mammary tumors in ovariectomized Sprague-Dawley rats. *Cancer Sci* 96, 19-25.

USEPA-U.S. Environmental Protection Agency, 2003. Reregistration Eligibility Decision for Diuron. List A. Case 0046. Office of Prevention, Pesticides and Toxic Substances. USEPA, Washington, DC, p. 106.

USEPA-U.S. Environmental Protection Agency, 2004. Chemicals Evaluated for Carcinogenic Potential. Office of Pesticide Programs, Health Effects Division. Science Information Management Branch, p. 22.

---

Valentovic, M. A., Yahia, T., Ball, J. G., Hong, S. K., Brown, P. I., and Rankin, G. O., 1997. 3,4-Dichloroaniline acute toxicity in male Fischer 344 rats. *Toxicology* 124, 125-34.

Vinggaard, A. M., Breinholt, V., and Larsen, J. C., 1999. Screening of selected pesticides for oestrogen receptor activation in vitro. *Food additives and contaminants* 16, 533-42.

Vinggaard, A. M., Hnida, C., Breinholt, V., and Larsen, J. C., 2000. Screening of selected pesticides for inhibition of CYP19 aromatase activity in vitro. *Toxicol In Vitro* 14, 227-34.

Xie, B., Tsao, S. W., and Wong, Y. C., 1999. Sex hormone-induced mammary carcinogenesis in female noble rats: the role of androgens. *Carcinogenesis* 20, 1597-606.

Wetzel, L. T., Luempert, L. G., 3rd, Breckenridge, C. B., Tisdell, M. O., Stevens, J. T., Thakur, A. K., Extrom, P. J., and Eldridge, J. C., 1994. Chronic effects of atrazine on estrus and mammary tumor formation in female Sprague-Dawley and Fischer 344 rats. *Journal of toxicology and environmental health* 43, 169-82.

### **Legend for Figures**

Figure 1 – Evolution of body weight in different groups during the experimental period.

Figure 2 - Immunohistochemically or HE-stained sections of mammary tumors from DMBA-initiated rats: A) PCNA-positive neoplastic cells (brown nuclei, 40x objective); B1 and 2) Apoptosis cells identified in HE-stained section (black arrows, 100x objective) or by expression of caspase-3-cleaved (black arrows, 60x objective), respectively; C) p63-positive myoepithelial cells (nucleus brown; 40x objective); D-E) Immunostaining for bak and bcl-2 mitochondrial proteins (brown-stained cytoplasm, 40x objective; F) Immunostaining for ER-alpha (brown nuclei; 40x objective).




Figure 1




Figure 2

Table 1 – Final body weights, body-weight gain, food and Diuron consumption and feed efficiency of different experimental groups at the end of the 25-week experiment.<sup>1</sup>

<i>Group/Treatment<sup>2</sup></i>		Effective number of rats (survivors)	Final body weights (g)	Body-weight gain <sup>3</sup> (g)	Food consumption (g/rat/day)	Feed efficiency <sup>4</sup>	Diuron consumption (mg/kg/day)
<i>Initiated</i>							
G1	DMBA	13	321.23 ± 36.13 <sup>a</sup>	114.85 ± 24.19 <sup>a</sup>	18.07 ± 2.08 <sup>a</sup>	0.17 ± 0.04 <sup>a</sup>	-
G2	DMBA+250 ppm	14	320.50 ± 30.79 <sup>a</sup>	119.79 ± 27.47 <sup>a</sup>	17.78 ± 2.54 <sup>b</sup>	0.15 ± 0.04 <sup>b</sup>	16.21 ± 2.43
G3	DMBA+1250 ppm	16	301.25 ± 28.44 <sup>a</sup>	97.81 ± 27.43 <sup>a</sup>	17.23 ± 1.72 <sup>c</sup>	0.19 ± 0.07 <sup>c</sup>	81.42 ± 9.12
G4	DMBA+2500 ppm	15	272.20 ± 31.69 <sup>b</sup>	77.20 ± 29.17 <sup>b</sup>	15.68 ± 1.66 <sup>d</sup>	0.22 ± 0.07 <sup>d</sup>	159.57 ± 17.35
<i>P value</i>			<i>P</i> < 0.001	<i>P</i> < 0.001	<i>P</i> < 0.001	<i>P</i> < 0.001	-
<i>Non-initiated</i>							
G5	Control	10	337.30 ± 24.10 <sup>a</sup>	122.30 ± 23.95 <sup>a</sup>	18.61 ± 1.75 <sup>a</sup>	0.16 ± 0.03 <sup>a</sup>	-
G6	2500 ppm	15	275.67 ± 14.41 <sup>b</sup>	66.20 ± 17.91 <sup>b</sup>	15.94 ± 1.76 <sup>b</sup>	0.23 ± 0.04 <sup>b</sup>	160.59 ± 18.61
<i>P value</i>			<i>P</i> < 0.001	<i>P</i> < 0.001	<i>P</i> < 0.001	<i>P</i> < 0.001	-

<sup>1</sup>Values are mean ± SD; <sup>2</sup>DMBA = (7,12-dimethylbenz[a]anthracene, 50 mg/kg i.g.) plus 250, 1250 or 2500 ppm of Diuron in diet. <sup>3</sup>Diuron exposure period (1<sup>st</sup> to the 25<sup>th</sup> week of the experiment);<sup>4</sup> Weight gain/food consumed. Groups G2, G3 and G4 and Group G6 were compared only to the respective control groups (groups G1 and G5, respectively).

Table 2 – Organ relative weights of the different experimental groups at the end of experiment.<sup>1</sup>

<i>Group/Treatment</i> <sup>2</sup>	Effective		Organs relative weight (%)						
	number of rats	(survivors)	Liver	Spleen	R Kidney <sup>3</sup>	L Kidney <sup>3</sup>	R Ovary	L Ovary	Uterus
<b><i>Initiated</i></b>									
G1	DMBA	13	3.33 ± 0.43 <sup>a</sup>	0.23 ± 0.06 <sup>a</sup>	0.30 ± 0.03	0.30 ± 0.04	0.08 ± 0.02	0.08 ± 0.03	0.92 ± 0.35
G2	DMBA+250 ppm	14	3.42 ± 0.40 <sup>a</sup>	0.34 ± 0.07 <sup>a</sup>	0.31 ± 0.02	0.31 ± 0.02	0.07 ± 0.02	0.08 ± 0.02	0.97 ± 0.20
G3	DMBA+1250 ppm	16	3.90 ± 0.49 <sup>b</sup>	0.46 ± 0.07 <sup>b</sup>	0.32 ± 0.03	0.32 ± 0.03	0.07 ± 0.01	0.08 ± 0.02	1.21 ± 0.58
G4	DMBA+2500 ppm	15	3.84 ± 0.39 <sup>b</sup>	0.50 ± 0.12 <sup>b</sup>	0.33 ± 0.06	0.31 ± 0.04	0.06 ± 0.02	0.06 ± 0.02	1.23 ± 0.60
<i>P value</i>			<i>P</i> = < 0.001	<i>P</i> < 0.001	<i>P</i> = 0.413	<i>P</i> = 0.136	<i>P</i> = 0.060	<i>P</i> = 0.074	<i>P</i> = 0.114
<b><i>Non-initiated</i></b>									
G5	Control	10	3.33 ± 0.45 <sup>a</sup>	0.20 ± 0.03 <sup>a</sup>	0.31 ± 0.02 <sup>a</sup>	0.31 ± 0.02 <sup>a</sup>	0.07 ± 0.03	0.09 ± 0.02 <sup>a</sup>	1.29 ± 0.98 <sup>a</sup>
G6	2500 ppm	15	4.18 ± 0.46 <sup>b</sup>	0.51 ± 0.07 <sup>b</sup>	0.36 ± 0.05 <sup>b</sup>	0.35 ± 0.08 <sup>b</sup>	0.06 ± 0.01	0.06 ± 0.02 <sup>b</sup>	1.02 ± 0.39 <sup>b</sup>
<i>P value</i>			<i>P</i> = < 0.001	<i>P</i> < 0.001	<i>P</i> = 0.026	<i>P</i> = 0.006	<i>P</i> = 0.120	<i>P</i> = 0.004	<i>P</i> = 0.803

<sup>1</sup>Values are mean ± SD; <sup>2</sup>DMBA= (7, 12-dimethylbenz(a)anthracene, 50 mg/kg i.g.) plus 250, 1250 or 2500 ppm of Diuron in diet; <sup>3</sup>R= Right, L= Left. Groups G2, G3 and G4 and Group G6 were compared only to the respective control groups (groups G1 and G6, respectively).

Table 3 – Hormonal plasma levels and mammary tumor data of DMBA-initiated groups.

	Group/Treatment <sup>1</sup>			
	G1	G2	G3	G4
	DMBA	DMBA+250 ppm	DMBA+1250 ppm	DMBA+2500 ppm
Effective number of rats	13	14	16	15
Hormone levels				
Estradiol (µg/ml)	29.67 ± 13.89	22.33 ± 8.65	26.66 ± 13.78	21.06 ± 9.99
Progesterone (ng/mL)	26.26 ± 15.53	23.39 ± 18.35	26.02 ± 18.75	11.31 ± 6.16
Period of tumor appearance (days)	83.13 ± 36.17	86.80 ± 37.07	84.00 ± 28.69	85.75 ± 42.53
Day of 1 <sup>st</sup> tumor	42°	35°	49°	49°
Incidence of tumor bearing rats (%) <sup>2</sup>	7/13 (53.8)	10/14 (71.4)	6/16 (37.5)	5/15 (33.3)
Multiplicity <sup>3</sup> (No./rat)	2.71 ± 1.70	1.90 ± 0.99	2.17 ± 0.75	1.67 ± 1.21
Tumor weight (g)	10.87 ± 11.85	9.64 ± 9.77	13.02 ± 8.38	14.86 ± 12.84
Total number of mammary tumors	21	20	11	8
Histological Types				
Fibroma	1 (4.7%)	0	0	0
Adenoma	1 (4.7%)	0	0	1 (12.5)
Adenocarcinoma	19 (91.5%)	20 (100%)	11 (100%)	7 (87.5%)

<sup>1</sup>DMBA = (7,12-dimethylbenz(a)anthracene, 50 mg/kg i.g.) plus 250, 1250 or 2500 ppm of Diuron in diet;

<sup>2</sup>Incidence: percentage of tumor-positive rats surviving for 23 or more weeks of Diuron treatment; <sup>3</sup>Multiplicity: average number of tumors/tumor-bearing rat. No significant different was observed among groups.

Table 4 – Growth kinetic and expression immunohistochemical of biomarkers in mammary neoplasms from DMBA-initiated groups.<sup>1</sup>

Group/Treatment <sup>2</sup>	Growth kinetic <sup>3</sup>		Immunohistochemical score <sup>4</sup>			
	PCNA LI%	AI%	ER-alpha	p63	bak	bcl-2
G1 DMBA	12.65 ± 7.14	0.57 ± 0.24	2.94 ± 1.78	1.89 ± 1.59	1.00 ± 0.63	2.33 ± 1.86
G2 DMBA+250 ppm	10.72 ± 4.99	0.57 ± 0.20	3.94 ± 1.69	3.42 ± 2.83	1.86 ± 2.27	2.00 ± 1.55
G3 DMBA+1250 ppm	12.84 ± 5.32	0.45 ± 0.14	2.14 ± 1.07	3.82 ± 2.99	1.63 ± 0.74	2.33 ± 2.16
G4 DMBA+2500 ppm	14.90 ± 4.86	0.58 ± 0.18	5.14 ± 2.48	2.13 ± 2.03	1.86 ± 1.68	2.29 ± 2.06

<sup>1</sup>Values are mean ± SD; <sup>2</sup>DMBA= (7, 12-dimethylbenz(a)anthracene, 50 mg/kg i.g.) plus 250, 1250 or 2500 ppm of Diuron in diet.; <sup>3</sup>PCNA labeling index and apoptosis index; <sup>4</sup>Score = Multiplication product of the proportion score and the intensity score. Groups G2, G3 and G4 were compared only to the respective control group (group G1). No significant different was observed among groups.



*Capítulo III*  
*Artigo Científico II*

**Early life stage exposure to the herbicide Diuron: effects on reproductive development and function and susceptibility to the mammary carcinogenesis in female Sprague Dawley rats.**

Tony F. Grassi<sup>1</sup>, Marina T. Guerra<sup>2</sup>, Juliana E. Perobelli<sup>2</sup>, Fabíola C. de Toledo<sup>2</sup>, Denise S. da Silva<sup>2</sup>, João Lauro Viana de Camargo<sup>1</sup>, Wilma de Grava Kempinas<sup>2</sup>, Luís Fernando Barbisan<sup>2\*</sup>

<sup>1</sup>Faculty of Medicine, UNESP - São Paulo State University, Department of Pathology, Botucatu-SP, Brazil

<sup>2</sup>Institute of Biosciences, UNESP - São Paulo State University, Department of Morphology, Botucatu-SP, Brazil

*\*Address correspondence to:*

Luís Fernando Barbisan, Ph.D

Departamento de Morfologia, Instituto de Biociências, Universidade Estadual Paulista (UNESP), Botucatu, 18618-000, SP, Brasil.

Telephone/Fax: 55-14-38116264

E-mail: [barbisan@ibb.unesp.br](mailto:barbisan@ibb.unesp.br)

*\*Artigo Científico de acordo com as normas da revista Reproductive Toxicology (ISSN: 0890-6238)*

---

**Abstract**

Diuron is widely used in agriculture and its deleterious effects on the reproductive system and mammary gland are still poorly known. Thus, this study evaluated if early life stage exposure to Diuron alter puberty onset or susceptibility to mammary carcinogenesis in female Sprague-Dawley (SD) rats. Pregnant rats received basal diet or diet containing Diuron at 500, 750 and 1250 ppm, from gestational day 12 (GD12) to the end of lactation period. After weaning, female offspring rats continued receiving basal diet or diet containing Diuron until PND 51. The animals were sacrificed on PND 51, 75 and 25-weeks after 7,12-dimethyl(a)anthracene (DMBA) administration. There was no significant difference among groups on vaginal opening, estrous cycle or mammary gland morphology or carcinogenesis. However, a reduction on ovary weight and corpora lutea was observed PND 75 in Diuron-treated 1250 ppm rats suggesting that Diuron exposure may have been toxic to the ovaries.

**Key words:** pesticides, Diuron, mammary carcinogenesis, Sprague-Dawley rats, maternal exposure, female offspring, reproduction

## 1. Introduction

Diuron [3-(3,4-dichlorophenyl)-1,1-dimethylurea] is a urea-derived herbicide acting by inhibiting photosynthesis in microorganisms and plants [1,2]. This pesticide is indicated for the control of weeds, as well as mosses, in non-crop areas and in many agricultural crops such as fruit, cotton, alfalfa, wheat and soy or as antifouling agent in aquatic environmental [1,2]. Due to its moderately to highly persistence, Diuron can be found in many environments such as soil, sediments and water [2,3].

Diuron *per se* has low systemic toxicity to mammals and birds, and moderate toxicity to aquatic invertebrates [2]. In mammals, it is biotransformed by dealkylation of methylureic groups of carbons two and/or six from the benzene ring via cytochrome (CYP) P450s enzymes, generating 3,4-dichlorophenyl and 3,4-dichloroaniline (3,4-DCA) [2-6]. Thus, a possible adverse effect could be operative for humans exposed to larger amounts of Diuron and that present a high CYP1A 1 and 2 contents, which may be able to metabolize Diuron more efficiently [7].

Several chemicals have been identified as endocrine disruptors, including natural and synthetic hormones, pesticides, plasticizers and industrial by-products which can interfere with hormone biosynthesis, metabolism, or action resulting in a deviation from normal homeostatic control or reproduction [8]. Some substituted urea herbicides are able to block or inactivate the steroid hormone receptors and/or affect the levels of sex or

pituitary hormones with potential to affecting the development and function of the male and female reproductive system [9-15]. Findings from *in vitro* assays indicate that Diuron did not inhibit 5alpha-reductase activity but has the capacity to connect to the androgen receptor, thus allowing that this herbicide to act as a male endocrine disruptor [11,16]. Besides, Diuron did not affect CYP19 aromatase activity in the human placental microsomes assay, indicating that this herbicide did not interfere in the conversion of androgens to estrogens, which could alter the balance between the male and female sex hormones [13,17]. *In vitro* assays indicated that this herbicide did not appear to show estrogenic activity in human MCF-7 breast cancer cells, Chinese hamster ovary cells or recombinant yeast strains [13-15].

Diuron have been considered an aryl hydrocarbon receptor (AhR) partial agonist with major efficacy in rat cells than in the mouse, guinea pig or human cell lines [18]. The AhR, known for mediating the toxicity of dioxins and related compounds, is a helix-loop-helix PAS-containing transcription factor which activates targets gene transcription in a ligand-dependent manner [19]. Some AhR ligand has been reported to induce formation of an AhR-estrogen receptor complex (Ahr/ER complex), which stimulates transcription of ER target genes [20,21,22]. There is an extensive evidence showing that crosstalk between the ER and AhR/aryl hydrocarbon receptor nuclear translocator (ARNT) heterodimer could be leads to inhibition/activation of estrogenic signaling both *in vitro* and *in vivo* [20,21,22]. Thus, Diuron could be

acting as an endocrine disruptor to the reproductive organs and mammary gland via activation of Ahr/ER complex.

In order to knowledge of possible adverse effects on reproductive toxicity and development from Diuron, the present study was delineated to investigate if early life stage (gestational, lactational and juvenile) exposure to the herbicide Diuron affect reproductive development and function and/or alter the susceptibility to the mammary carcinogenesis in adult female Sprague Dawley rats.

## 2. Material and Methods

### 2.1. Animals and Treatments

The animals were handled in accordance with Ethical Principles for Animal Research adopted by the Brazilian College of Animal Experimentation (COBEA) and approved by the Committee for Ethics in Animal Experimentation of the Faculty of Medicine, UNESP, Botucatu-SP, Brazil (Protocol n° 523).

Sprague-Dawley (SD) outbred male and female rats were obtained from colonies under SPF-conditions from Multidisciplinary Center for Biological Investigation (CEMIB-UNICAMP, Campinas-SP, Brazil). The animals were housed in polypropylene cages with white pine shavings autoclaved and maintained in rooms under controlled environmental conditions (temperature  $22 \pm 2^{\circ}\text{C}$ , relative humidity  $55 \pm 20\%$ , a 12/12h light-dark cycle and 4 daily exhaust periods). All animals received Nuvilab CR-1 commercial chow (Nuvital, PR, Brazil), filtered drinking water *ad libitum*.

After a 2-week acclimation period, 8-week-old female SD rats (n=26) were mated to 12-week-old male SD rats (n=12) by placing two females in a cage with one male. Mating was realized during the dark period of the cycle and the gestational day (GD) 0 was determined by the presence of sperm in vaginal smears of females in estrus (sexually receptive). The pregnant or lactating dams were weighed on alternating days to permit calculation of food and Diuron intake and investigation of clinical signs of maternal toxicity. Data

for food and water consumption of dams and litters were registered during the experimental period.

Pregnant SD rats were non-treated or orally treated with 250, 500 e 1250 ppm of Diuron in the basal diet from day GD 12 up to GD 21 to the end of lactation period (postnatal day 21- PND21). After weaning, female offspring were fed basal diet or basal diet containing Diuron at 250, 500 e 1250 ppm until PND 51. Some female were sacrificed on PND 51 (mammary gland and hormonal analysis), PND 75 (reproductive organs and hormonal analysis) or 25-weeks after 7,12-dimethyl(a)anthracene (DMBA) administration for initiation of mammary carcinogenesis.

## **2.2. Reproductive organs development and function**

### **2.2.1. External signs of puberty onset and estrous cycle**

The time of vaginal opening (VO, assessed daily starting at PND 30) was registered as an indicator of puberty. All female offspring rats from Diuron-treated 500, 750 and 1250 ppm and non-treated groups were evaluated daily and the day of complete VO was adequately recorded. On PND 60, the estrous cyclicity of female offspring rats was assessed on cells from daily vaginal smears, collected over a period of 15 days. Every morning 10  $\mu$ L of 0.9% saline solution was instilled into the vagina and subsequently aspirated. The material was observed under light microscopy and the estrous cycle phase was determined by cytology [23]. The total frequency of each

phase for every rat observed in this period was used to calculate the total length of the proestrus, estrus, metaestrus and diestrus (in days) and the estrous cycle length.

### **2.2.2. Analysis of reproductive organs**

At PND 75, ovaries and uteri from Diuron-treated 750 and 1250 ppm and non-treated groups were collected of female offspring rats in estrus phase, weighed on precision balance, fixed in Alfac's solution, dehydrated in ethanol and embedded in paraplast. Three sections (5  $\mu\text{m}$ ) per animal, with 50  $\mu\text{m}$  of distance among them, were obtained, mounted on glass slides and stained with hematoxylin and eosin. In each ovary, ovarian follicles and corpora lutea were counted in 3 sections per animal and expressed as number per unit area ( $\text{mm}^2$ ). Follicles were classified according to Guerra et al. (2009). [23] Primordial and primary follicles were enumerated together; oocytes surrounded by a single layer of either squamous or cuboidal epithelial cells were included. Follicles were classified as pre-antral when containing 2–4 layers of granulosa cells with no antral space. Antral follicles were classified when containing three or more layers of granulosa cells and a clearly defined antral space. Characteristics of atretic follicles included pyknotic granulosa cells, disorganized granulosa cells, degenerating oocyte and detachment from the basement membrane. In the uterus, the endometrial height was measured, in 3 sections per animal using a light microscope. In each section, five

different regions were analyzed, resulting in a total of 15 measurements per animal.

### **2.2.3. Hormonal analysis**

Female offspring rats were sacrificed on PND 51 and 75, during the estrus phase, between 8:00 and 10:00 a.m. After decapitation, trunk blood was collected and allowed to clot on a refrigerator (4 C) for 30 min. Serum was collected after centrifugation and stored at -20 C until analysis. At PND 75, serum FSH and LH concentrations were measured using a double-antibody radioimmunoassay (RIA) kit (National Institute of Arthritis, Diabetes and Kidney Diseases–NIADDK, USA). At PND 51, estrogen and progesterone levels were determined by means of automatic equipment (VITROS ECi-Johnson and Johnson Ultra-Sensitive Chemiluminescence analysis, USA) using specific reagents supplied by Johnson and Johnson Orthoclinical (São Paulo-SP, Brazil). All the samples were analyzed at the same assay to avoid inter-assay variability.

## **3. Effects of Diuron exposure in early life stage on mammary gland development and tumorigenesis**

### **3.1 Analysis of the mammary gland morphology and function**

At PND 51, female offspring rats were sacrificed and whole skin with mammary glands were removed and fixed for 24h in 10% phosphate-buffered

formalin. Samples of organs/tissues were processed in order to provide 5  $\mu$ m thick paraffin sections for histological (hematoxylin-eosin – H&E) and immunohistochemical analysis for proliferating cell nuclear antigen (PCNA), cleaved caspase -3 and estrogen-receptor-alpha (ER- $\alpha$ ).

Mammary tissue sections were put on poly-l-lysine coated slides, desparaffinized and rehydrated with graded alcohol. Sections were subjected to microwave antigen retrieval in citric acid buffer at pH 6.0 for 3 x 5 min (PCNA and caspase-3 markers) or Pascal pressure chamber retrieval in citrate acid buffer at pH 6.0 at 120°C for 3 min (estrogen receptor-alpha marker). Endogenous peroxidase was blocked with 3% H<sub>2</sub>O<sub>2</sub> in phosphate-buffered saline (PBS) for 10 min in dark. After washing with PBS, slides were incubated with non-fat milk in PBS for 60 min. Sections were then incubated with primary antibodies mouse monoclonal anti-PCNA/PC10 (1:200 dilution) (DakoCytomation Denmark A/S, Glostrup, Denmark), rabbit polyclonal anti-cleaved caspase-3 /Asp 175 rabbit (1:100 dilution) (Cell Signaling Technology Inc., Danvers, MA - USA) and mouse monoclonal anti-ER- $\alpha$ /6F11 (1:50 dilution) (BioCare Medical – Concord, CA – USA) for overnight. This was followed by secondary antibodies anti-mouse and anti-rabbit conjugated with polymer/peroxidase (Max Polymer, Novolink TM - Novocastra TM- Leica Microsystems, UK) for 30 min at room temperature. Chromogen color development was accomplished with 3,3'-diaminobenzidine tetrahydrochloride (DAB, Sigma-Aldrich Co.) as the substrate to demonstrate

the sites of peroxidase binding. The slides were counterstained with Harris's hematoxylin. A negative control was performed in all cases by omitting incubation with the primary antibodies, which in all instances resulted in negative immunoreactivity.

The PCNA S-phase, caspase-3 cleaved and ER- $\alpha$  labeling indexes in mammary glands were calculated as the number of positively marked cells divided by the total number of cells scored  $\times 100$  ( $\sim 300$  to 500 epithelial cells in each section).

### **3.2 Mammary carcinogenesis assay**

On PND 51, female offspring rats from Diuron-treated at 500, 750 and 1250 ppm and non-treated groups (12 rats/group, 2 female/litter) received a single intragastric (i.g.) dose of 50 mg/kg body weight (b.w.) of DMBA. After DMBA administration, all groups received basal diet and drinking water ad libitum for 25 weeks. During the experimental period, the animals were carefully checked once a week for the presence of gross mammary tumors; data on the number and localization of each palpable mass in the six mammary complexes were recorded. Sacrificed moribund rats and deceased animals were autopsied. Moribund and surviving rats were included in the effective number of rats for histopathology analysis. All animals were euthanatized in estrus phase by exsanguination between 9:00 to 11:00 hr, under sodium pentobarbital anesthesia (45 mg/kg b.w.).

At necropsy, mammary tumors, ovaries, uterus and vagina were removed and fixed for 24h in 10% phosphate-buffered formalin. Before fixation, mammary tumors, ovaries and uterus were weighed. Samples of organs/tissues/tumors were processed in order to provide 5  $\mu$ m thick sections for histological analysis. Proliferative or neoplastic lesions in mammary glands and in reproductive system (i.e., ovary, uterus, cervix and vagina) were classified according to published criteria by The Society of Toxicologic Pathology (SSNDC Guides, 2006). [24]

#### **4. Statistical Analysis**

Data for body weight and body-weight gain, food consumption, tumor weights, ovary and uterus weights, reproductive parameters and FSH, LH, estrogen and progesterone serum levels were analyzed by ANOVA when the results presenting normal distribution or Kruskal-Wallis test when this did not occur. Analyses of the semi-quantitative combined scores were performed using the Kruskal-Wallis test. Contrast among groups was analyzed by the Tukey or Student-Newman-Keuls methods. Incidences of mammary tumor were examined using the chi-squared or the Fischer test. Significant differences were assumed when  $P < 0.05$ . The statistical analyses were performed using the Jandel Sigma Stat software (Jandel Corporation, San Rafael, CA, USA).

### 3. Results

#### 3.1. Effects of early life Diuron exposure on dams (F0) and females offspring

Dam weight was recorded during GD12-20 Diuron exposure period and weight gain was compared among groups (Table 1). Dams treated with Diuron 1250 ppm gained less weight and presented a significantly lower body weight at DG20 than control dams (G1 group vs. G4 group,  $P = 0.042$ ). Female offspring rats) exposed to Diuron during gestation, lactation and pre-puberty presented a significantly lower body weight at PND 10 (750 and 1250 ppm), PND 21 (500, 750 and 1250 ppm) and PND 51 (1250 ppm) when compared to female pups non-treated ( $0.042 < P < 0.001$ ). During PND 21-51, no significant difference in food consumption was observed among female offspring treated or non-treated (Table 1).

#### 3.2. Effects of early life Diuron exposure on reproductive and mammary parameters in females offspring

Vaginal opening (all groups) and estrous cyclicity (Diuron-treated 750 and 1250 ppm and non-treated groups) were evaluated as physical signs of female reproductive development. Following VO, estrous cyclicity patterns of these animals were observed until PND 60. The age at vaginal opening was not significantly altered, occurring on days  $39.08 \pm 0.67$  (n=6 litters),  $39.42 \pm 1.31$  (n=6 litters),  $38.70 \pm 0.63$  (n=6 litters),  $39.25 \pm 1.10$  (n=6 litters) for non-

treated and early in life exposure to Diuron at 500, 750 and 1250 ppm groups, respectively. Also, no significant difference due to early in life exposure to Diuron was observed from analysis of estrous cyclicity in female offspring rats (Table 2). Besides, ovary, uterus morphology analysis and FSH and LH serum concentrations were also evaluated at PND75. Absolute ovary weight and corpora lutea counting was lower in Diuron-treated 1250 ppm and 750 and 1250 ppm groups, respectively, when compared to the female offspring rats from non-treated group (Table 2). For others reproductive parameters including FSH and LH serum levels found no significant difference among groups (Table 2 and Figure 1).

In addition to the traditional indicators of rat puberty, mammary gland development was also evaluated in female offspring at PND51. To evaluate the effects of Diuron following gestational, lactational and pre-puberty exposure were evaluated progesterone, estrogen levels and morphology (all groups) and growth (cell proliferation and apoptosis analysis) and ER- $\alpha$  expression in histological sections from Diuron-treated 1250 ppm and non-treated groups. At PND 51, no significant alterations in estradiol and progesterone serum levels was observed among Diuron-treated 750 and 1250 ppm and non-treated groups (Figure 1). Female offspring Diuron-treated 1250 ppm had mammary gland morphology with a normal appearance of lobular/acinar units surrounded by abundant adipose tissue similar to the non-treated animals (data not shown). Moreover, Diuron-treatment at 1250 ppm

did not alter the PCNA, cleaved caspase-3 labeling indexes or the immunoreactivity for ER- $\alpha$  in the mammary gland sections (Figure 2).

### **3.3. Effects of early life Diuron exposure on mammary carcinogenesis susceptibility**

To evaluate if exposure to Diuron early in life would elicit developmental changes in the mammary tissue and cause a predisposition for mammary cancer, female offspring were initiated with DMBA at PND 51. At the end of experiment at week 25, survival rates were 66.67% in DMBA-initiated group (G1), 100%, 75% and 66.67% in early life Diuron-treated 500 (G2), 750 (G3) and 1250 ppm (G4) and DMBA-initiated groups, respectively (Table 3). Final body weight were significantly reduced ( $P = 0.010$ ) in early life Diuron-treated 1250 ppm and DMBA-initiated group (G4) when compared to solely DMBA-initiated group (G1). Diuron early in life exposure and DMBA initiation did not alter the body-weight gain or ovary and uterus weights when compared to respective control group (G1) (Table 3).

Data from mammary tumor analysis in DMBA-initiated groups collected during experimental period is presented in Table 4. More than 50% of the animals developed mammary tumors histologically classified as fibroma (15.2%) and adenocarcinoma (84.9%). In general, mammary adenocarcinomas induced by DMBA presented an expansive pattern with local invasive areas. Exposure to Diuron early in life did not alter the latency period (i.e., time to

---

first palpable mammary tumor), incidence, multiplicity, tumor weights or histopathologic patterns in adult female SD rats initiated with DMBA for any treatment group (Table 4).

#### 4. Discussion and Conclusions

Diuron and others pesticides with potential endocrine disrupting properties have been categorized as potential mammary carcinogens in rodent carcinogenesis assays [25,26]. These pesticides, including some substituted urea herbicides, are able to block or inactivate the steroid hormone receptors and/or affect the levels of pituitary hormones with potential to alter the development and function of the male and female reproductive systems [10,13,14,15,16,17]. Thus, the current study was performed to assess the potential adverse of early life stage exposure to the herbicide Diuron on reproductive system and mammary gland development since during these critical phases of development (i.e., *in utero*, lactation and pre-puberty) the fetuses and newborns appear to be more sensitive than adults to endocrine disruption [27,28].

Analysis of body weight through the course of the experiment supplies data on the general health of the animal and can be important in interpreting the effects of a toxic substance on the reproductive system. A sharp decline in animal body weight may be a consequence of systemic toxicity [29]. The decrease in body weight of the dams treated with Diuron at 1250 ppm observed in our study may be related to fewer pups, although this parameter is not statistically significant, or even then represent a sign of maternal toxicity. Our results corroborates with Khera (1979) [30], which administered Diuron in doses of 250 e 500 mg/b.wt. at DG 15 and 22, found a decrease in body

weight of dams, suggesting that Diuron increased incidence of maternal toxicity in these experimental conditions. In a previous study, a decrease in number of fetuses in female rats inseminated by males treated with the dose of 125 mg/kg was observed, indicating a possible increase in number of resorptions and in frequency of post-implantation losses [31]. Besides, the reduction in body weight of female offspring during treatment indicates that Diuron may have interfered with growth and development of these animals in this critical development period. Thus, the treatment with Diuron caused a significant reduction in weight of mothers and of uteruses with fetuses.

In the present study, the herbicide Diuron was incorporated into chow, which could have made it less palatable, leading to diminished intake by rats or even rejection of the diet containing chemicals [32]. However, the consumption of basal diet containing Diuron was similar among the experimental groups showing that the observed body weight reduction in dams and female pups was not related to food consumption.

Puberty, an event indicated by the age of vaginal opening and a gradual increase in the secretion of gonadotropic hormones by the pituitary, which leads, in turn, to an increase in blood estradiol levels [29,33]. In the present study, no significant changes were observed in the day of vaginal opening among the groups, indicating absence of an adverse effect of Diuron on puberty onset. Sex steroids influence the growth, function and differentiation of female reproduction organs and make them susceptible to endocrine

disruption. During the estrous cycle, fluctuating levels of estrogens and progesterone elicit profound effects on epithelial proliferation and cytodifferentiation [34]. In this study, no alterations in uterine endometrial height and estrous cycle was observed in the female offspring rats exposed to Diuron in early in life, indicating normal hormonal responsiveness of the female reproductive tract, a finding supported by hormonal results, whereas no difference in LH and FSH serum levels among groups was observed.

Significant increases or decreases in ovarian weight compared with controls should be considered an indication of female reproductive toxicity. Although ovarian function shifts throughout the estrous cycle, ovarian weight in the normal rat does not show significant fluctuations. Still, changes as inhibition of corpus luteum formation may be associated with changes in ovarian weight [29]. The reduction of ovarian weight observed in female pups treated with Diuron at 750 and 1250 ppm was correlated with a decrease in number of corpora lutea, indicating a possible toxic action of Diuron on this organ. In the chronic toxicity study in Wistar rats, no significant effects on the female reproductive system were observed in the animals examined at 12 months [35]. Moreover, the possible impact of treatment with the herbicide Diuron on ovary morphology and function requires further examination.

The exposure to Diuron during critical period of development of the mammary gland did not induced delayed development (atrophy) or tubuloalveolar hyperplasia or serum progesterone and estradiol levels,

which biomarkers indicative of endocrine-disrupting effects [36]. Also, Diuron-treatment did not alter the levels of cell proliferation (PCNA marker) and apoptosis (cleaved caspase-3 marker) neither the immunoreactivity for estrogen receptor alpha in alveolar and ductal epithelial mammary cells. Thus, the herbicide Diuron did not induce systemic hormonal perturbation or mammary changes in conditions of present experiment.

7,12-Dimethylbenz[a]anthracene (DMBA) is a prototype carcinogen that induces mammary carcinogenesis in rodents DMBA. It is a procarcinogen that requires metabolic conversion to its ultimate carcinogenic metabolite by oxidation, which is conducted by CYP1A1 and 1B1 (CYP1) the CYP1A1 and CYP1B1 (CYP1) [37]. Both Diuron and DMBA bind and activate the aryl hydrocarbon receptor (AhR) [38], resulting in activation of AhR and subsequent nuclear translocation, where it heterodimerizes with another bHLH partner, the AhR nuclear translocator protein (ARNT) [39]. The AhR–ARNT dimer binds to specific regulatory elements, xenobiotic responsive elements (XREs), upstream of the responsive genes and enhances their transcripts, the CYP1 enzyme family which is a basic helix–loop–helix (b-HLH) protein. As liver is a primary role in the biotransformation of both DMBA and Diuron involving CYP1 enzyme family and centrilobular hypertrophy induced by Diuron has been described [31, 40], we hypothesized that an exposure to Diuron early in life could produce the biological character to potentially increase the risk of DMBA-induced mammary carcinoma.

However, our findings indicate that Diuron did not interfere in development of mammary neoplasms when latency period, incidence, multiplicity, tumor weights or histopathologic patterns were investigated.

No studies of human exposure and developmental and reproductive effects were located and a few reports in the literature on reproductive toxicity of Diuron in female rat have been described [41]. This present study provide the first evidence that early life stage exposure to the herbicide Diuron did not modify mammary gland development and carcinogenesis in adult female Sprague-Dawley rats but the impact on ovary morphology and function requires further examination.

## **5. Acknowledgments**

This study was supported by FAPESP - State of São Paulo Research Foundation, grant 2006/01330-0.

---

## 6. References

- [1] Liu J. Phenylurea herbicides. In: Krieger KE (Ed.), Handbook of Pesticides Toxicology—Agents. Academic Press San Diego 2001: 1521–1523.
- [2] Giacomazzi S, Cochet N. Environmental impact of diuron transformation: a review. Chemosphere 2004; 56: 1021-32.
- [3] Iyer P. Evidence on the developmental and reproductive toxicity of diuron. 2002; OEHHA, Sacramento. Available in: <http://www.oehha.ca.gov/prop65/hazard ident/pdf zip/diuronhid.pdf>.
- [4] Verheij ER, van der Greef J, La Vos GF, van der Pol W, Niessen WM. Identification of diuron and four of its metabolites in human postmortem plasma and urine by LC/MS with a moving-belt interface. J Anal Toxicol 1989; 13: 8-12.
- [5] Van Boven M, Laruelle L, Daenens P. HPLC analysis of diuron and metabolites in blood and urine. J Anal Toxicol 1990; 14: 231-4.

- 
- [6] Nguyen JV, Olsson AO, Bravo R, Needham LL, Barr DB. Quantification of atrazine, phenylurea, and sulfonylurea herbicide metabolites in urine by high-performance liquid chromatography-tandem mass spectrometry. *J Anal Toxicol* 2007; 31: 181-6.
- [7] Abass K, Reponen P, Turpeinen M, Jalonen J, Pelkonen O. Characterization of diuron N-demethylation by mammalian hepatic microsomes and cDNA-expressed human cytochrome P450 enzymes. *Drug Metab Dispos* 2007; 35:1634-41.
- [8] Diamanti-Kandarakis E, Bourguignon JP, Giudice LC, Hauser R, Prins GS, Soto AM, et al. Endocrine-disrupting chemicals: an Endocrine Society scientific statement. *Endocr Rev* 2009; 30: 293-342.
- [9] Stevens JT, Breckenridge CB, Wetzel L. A risk characterization for atrazine: oncogenicity profile. *J Toxicol Environ Health A* 1999; 56: 69-109.
- [10] Cook JC, Mullin LS, Frame SR, Biegel LB. Investigation of a mechanism for Leydig cell tumorigenesis by linuron in rats. *Toxicol Appl Pharmacol*, 1993. 119: 195-204

- 
- [11] Wetzel LT, Luempert LG, 3rd, Breckenridge CB, Tisdell MO, Stevens JT, Thakur AK, et al. Chronic effects of atrazine on estrus and mammary tumor formation in female Sprague-Dawley and Fischer 344 rats. *J Toxicol Environ Health* 1994; 43: 169-82.
- [12] Stevens JT, Breckenridge CB, Wetzel L. A risk characterization for atrazine: oncogenicity profile. *J Toxicol Environ Health A* 1999; 56: 69-109.
- [13] Vinggaard AM, Breinholt V, Larsen JC. Screening of selected pesticides for oestrogen receptor activation *in vitro*. *Food Addit Contam* 1999; 16: 533-42.
- [14] Vinggaard AM, Hnida C, Breinholt V, Larsen JC. Screening of selected pesticides for inhibition of CYP19 aromatase activity *in vitro*. *Toxicol In Vitro* 2000; 14: 227-34.
- [15] Kojima H, Katsura E, Takeuchi S, Niiyama K, Kobayashi K. Screening for estrogen and androgen receptor activities in 200 pesticides by *in vitro* reporter gene assays using Chinese hamster ovary cells. *Environ Health Perspect* 2004; 112: 524-31.

- 
- [16] Noguerol TN, Boronat S, Casado M, Raldua D, Barcelo D, Pina B. Evaluating the interactions of vertebrate receptors with persistent pollutants and antifouling pesticides using recombinant yeast assays. *Anal Bioanal Chem* 2006; 385: 1012-9.
- [17] Bauer ER, Meyer HH, Stahlschmidt-Allner P, Sauerwein H. Application of an androgen receptor assay for the characterisation of the androgenic or antiandrogenic activity of various phenylurea herbicides and their derivatives. *Analyst* 1998; 123: 2485-7.
- [18] Lo S, King I, Allera A, Klingmuller D. Effects of various pesticides on human 5alpha-reductase activity in prostate and LNCaP cells. *Toxicol In Vitro* 2007; 21: 502-8.
- [19] Zhao B, Baston DS, Hammock B, Denison MS. Interaction of diuron and related substituted phenylureas with the Ah receptor pathway. *J Biochem Mol Toxicol* 2006; 20: 103-13.
- [20] Hankinson O. The aryl hydrocarbon receptor complex. *Annu Rev Pharmacol Toxicol* 1995; 35: 307-40.

- 
- [21] Safe S; Wormke M. Inhibitory aryl hydrocarbon receptor-estrogen receptor alpha cross-talk and mechanisms of action. *Chem Res Toxicol* 2003; 16: 807-16.
- [22] Swedenborg E, Pongratz I. AhR and ARNT modulate ER signaling. *Toxicology* 2009.
- [23] Guerra MT, Scarano WR, de Toledo FC, Franci JA, Kempinas WD. Reproductive development and function of female rats exposed to di-eta-butyl-phthalate (DBP) *in utero* and during lactation. *Reprod Toxicol* 2009 Oct 20.
- [24] Standardized System of Nomenclature and Diagnostic Criteria (SSNDC) Guides2006. Society of Toxicologic Pathology. [www.toxpath.org/ssndc.asp](http://www.toxpath.org/ssndc.asp).
- [25] Ueda M, Imai T, Takizawa T, Onodera H, Mitsumori K, Matsui T, et al. Possible enhancing effects of atrazine on growth of 7,12-dimethylbenz(a) anthracene-induced mammary tumors in ovariectomized Sprague-Dawley rats. *Cancer Sci* 2005 Jan; 96(1):19-25.

- 
- [26] Rudel RA, Attfield KR, Schifano JN, Brody JG. Chemicals causing mammary gland tumors in animals signal new directions for epidemiology, chemicals testing, and risk assessment for breast cancer prevention *Cancer*. 2007 Jun 15; 109(12 Suppl):2635-66.
- [27] Bigsby R, Chapin RE, Daston GP, Davis BJ, Gorski J, Gray LE, et al. Evaluating the effects of endocrine disruptors on endocrine function during development. *Environmental health perspectives* 1999 Aug; 107 Suppl 4:613-8.
- [28] Hendry WJ, 3rd, Sheehan DM, Khan SA, May JV. Developing a laboratory animal model for perinatal endocrine disruption: the hamster chronicles. *Exp Biol Med* (Maywood) 2002 Oct; 227(9):709-23.
- [29] United State Environmental Protection Agency—USEPA. Reproductive toxicity risk assessment guidelines, vol. 61. United State Environmental Protection Agency—USEPA 1996 p. 56273–322.
- [30] Khera KS, Whalen C, Trivett G, Angers G. Teratogenicity studies on pesticidal formulations of dimethoate, diuron and lindane in rats. *Bulletin of environmental contamination and toxicology* 1979 Jul; 22(4-5):522-9.

- 
- [31] Fernandes GS, Arena AC, Fernandez CD, Mercadante A, Barbisan LF, Kempinas WG. Reproductive effects in male rats exposed to diuron. *Reprod Toxicol* 2007 Jan; 23(1):106-12.
- [32] Clegg ED, Perreault D, Klinefelter GR. Assessment of male reproductive toxicity. In: Hayes AW, editor. *Principles and methods of toxicology*. Philadelphia: Taylor & Francis 2001. p. 1263–300.
- [33] Guyton AC, Hall JE. Fisiologia Feminina antes da Gravidez e os Hormônios Femininos. In: Guyton AC, Hall JE, editors. *Tratado de fisiologia médica*. Rio de Janeiro: Guanabara Koogan 2002 p. 869–82.
- [34] Boutin EL, Cunha GR. Estrogen-induced epithelial proliferation and cornification are uncoupled in sinus vaginal epithelium associated with uterine stroma. *Differentiation* 1997 Dec;62(4):171-8.
- [35] Bayer Institute of Toxicology. Diuron: Study for chronic toxicity and carcinogenicity with Wistar rats (administration in the diet for up to two years). Wuppertal: Bayer Institute of Toxicology 1985. (DPR # 106-035).

- 
- [36] Lucas JN, Rudmann DG, Credille KM, Irizarry AR, Peter A, Snyder PW. The rat mammary gland: morphologic changes as an indicator of systemic hormonal perturbations induced by xenobiotics. *Toxicol Pathol* 2007; 35(2):199-207.
- [37] Vinothini G, Murugan RS, Nagini S. Evaluation of molecular markers in a rat model of mammary carcinogenesis. *Oncol Res* 2009;17(10):483-93.
- [38] Wakui S, Yokoo K, Takahashi H, Muto T, Suzuki Y, Kanai Y, et al. Prenatal 3,3',4,4',5-pentachlorobiphenyl exposure modulates induction of rat hepatic CYP 1A1, 1B1, and AhR by 7,12-dimethylbenz[a]anthracene. *Toxicol Appl Pharmacol* 2006 Feb 1;210(3): 200-11.
- [39] Wakui S, Yokoo K, Takahashi H, Muto T, Suzuki Y, Kanai Y, et al. CYP1 and AhR expression in 7,12-dimethylbenz[a]anthracene-induced mammary carcinoma of rats prenatally exposed to 3,3',4,4',5-pentachlorobiphenyl. *Toxicology*.2005 Aug 1;211(3): 231-41.

- 
- [40] Grassi TF, Tararam CA, Spinardi-Barbisan AL, Domingues MA, de Camargo JL, Barbisan LF. Diuron lacks promoting potential in a rat liver bioassay. *Toxicol Pathol* 2007;35(7): 897-903.
- [41] United State Environmental Protection Agency—USEPA. Chemicals Evaluated for Carcinogenic Potential. Office of Pesticide Programs, Health Effects Division. Science Information Management Branch 2004.

### Legend for Figures

Figure 1 - Hormonal serum levels: PND 51- Estradiol (pg/ml) and Progesterone (ng/ml); PND 75- LH (ng/ml) and FSH (ng/ml).

Figure 2 – Mammary gland sections from female offspring rats at PND 51: A) PCNA-positive epithelial cells (brown nuclei, 60x objective); B) Apoptotic bodies identified by expression of cleaved caspase-3 (black arrows, 100x objective) and C) ER- $\alpha$ -positive epithelial cells (brown nuclei; 60x objective). A1-C1) PCNA, cleaved caspase-3, and ER- $\alpha$ -positive labeling indexes (LI%) in the mammary gland from non-treated and Diuron 1250 ppm treated groups, respectively. No significant difference was observed between groups.




Figure 1




Figure 2

Table 1- Reproductive outcomes from dams and female offspring rats in Diuron-treated and non-treated groups.<sup>1</sup>

Parameters	Group/Treatment <sup>2</sup>			
	G1	G2	G3	G4
	Non-treated	Diuron 500 ppm	Diuron 750 ppm	Diuron 1250 ppm
<b>Dams</b>				
Gestation length (days)	21.40 ± 9.57	21.43 ± 8.10	21.50 ± 8.78	21.50 ± 8.78
Litter size	11.40 ± 5.10	12.57 ± 4.75	13.67 ± 5.58	9.67 ± 3.95
Sex ratio (F:M)	1.03 ± 0.46	1.26 ± 0.48	1.33 ± 0.54	2.45 ± 1.00
Body weight (g) at GD20 <sup>o</sup>	364.0 ± 148.60	352.0 ± 133.04	391.3 ± 159.76	316.5 ± 129.21*
Body weight gain (g) (GD12 -GD 20)	80.17 ± 32.73	73.86 ± 27.92	87.67 ± 35.79	52.00 ± 21.23
<b>Female pups</b>				
Body weights (g)				
PND 10	18.62 ± 3.65	17.80 ± 2.68	16.18 ± 2.70**	16.39 ± 2.85**
PND 21	41.53 ± 8.31	34.67 ± 5.23**	37.11 ± 6.19**	37.45 ± 6.62**
PND 51	180.67 ± 52.15	180.58 ± 52.13	173.75 ± 50.16	160.50 ± 46.33***
Food consumption	(g/rat/day)	(g/rat/day)	(g/rat/day)	(g/rat/day)
Diuron intake	13.68 ± 2.14	13.13 ± 2.13	14.25 ± 2.23	12.61 ± 1.97
(PND 21-PND51)	(mg/rat/day)	(mg/rat/day)	(mg/rat/day)	(mg/rat/day)
	0	6.67 ± 1.07	10.69 ± 1.67	15.76 ± 2.46

<sup>1</sup>Values are mean ± S.E.M.; <sup>2</sup>500, 750 or 1250 ppm of Diuron in basal diet. Different from G1 group,

\**P* = 0.042, \*\* *P* < 0.001 and \*\*\**P* = 0.003.

Table 2 - Assessment of estrous cycle length and frequency of each phase over a 15-day period of evaluation in the female offspring on PND 60<sup>1</sup>.

<b>Estrous cycling</b>	<b>G1</b>	<b>G3<sup>2</sup></b>	<b>G4</b>
	Non-treated	Diuron 750 ppm	Diuron 1250 ppm
Number of females evaluated / litters	14 / 4	9 / 3	10 / 3
Estrous cycle length (days)	2.75 (2.38 - 3.25)	3.00 (2.67 - 3.25)	3.00 (2.50 - 3.00)
Frequency of proestrus (days)	3.25 (3.00 - 4.38)	3.33 (3.29 - 3.42)	3.30 (3.15 - 4.03)
Frequency of estrus (days)	3.38 (2.69 - 3.63)	3.00 (2.88 - 3.00)	2.75 (1.71 - 2.88)
Frequency of metaestrus (days)	6.25 (5.94 - 6.56)	5.75 (5.63 - 6.71)	7.00 (6.75 - 7.50)
Frequency of diestrus (days)	1.88 (1.44 - 2.13)	3.00 (2.00 - 3.13)	2.00 (1.38 - 2.50)

<sup>1</sup>Values are expressed median (Q1 quartile–Q3 quartile). <sup>2</sup>750 or 1250 ppm of Diuron in basal diet.

No significant different was observed among groups.

Table 3- Body weight, absolute and relative organ weights and ovarian and uterus analysis in the female offspring (PND75) in estrus phase.<sup>1</sup>

Parameters	Group/Treatment <sup>2</sup>		
	G1	G3	G4
	Non-treated	Diuron 750 ppm	Diuron 1250 ppm
<b>General</b>	(9 litters)	(9 litters)	(9 litters)
Body weight (g)	254.66 ± 7.21	239.31 ± 4.18	235.34 ± 6.93
Ovaries (mg)	84.44 ± 5.23	71.89 ± 1.70	67.33 ± 3.65*
Ovaries/body weight (mg/g)	0.33 ± 0.01	0.30 ± 0.01	0.29 ± 0.02
Uterus with fluid (mg)	598.56 ± 52.42	635.78 ± 68.61	728.44 ± 73.58
Uterus with fluid/body weight (mg/g)	2.36 ± 0.20	2.67 ± 0.30	3.09 ± 0.29
<b>Structures</b>	(6 litters)	(6 litters)	(6 litters)
Primordial and primary follicles	16.33 ± 2.59	12.40 ± 2.77	15.4 ± 5.37
Pre antral follicles	12.17 ± 1.58	8.40 ± 1.50	10.6 ± 1.70
Antral follicles	9.33 ± 1.80	6.20 ± 1.85	6.80 ± 1.16
Atretic follicles	12.67 ± 1.76	11.40 ± 1.86	13.00 ± 3.02
Corpora lutea	32.67 ± 2.42	18.80 ± 2.85*	19.60 ± 2.69*
Thickness of uterine endometrium	632.40 ± 39.22	596.54 ± 39.79	515.54 ± 86.64

<sup>1</sup>Values are mean ± S.E.M.; <sup>2</sup>750 or 1250 ppm of Diuron in basal diet. Different from G1 group,

\**P*<0.01.

Table 4 – Data from body weights, body-weight gain and ovary and uterus relative weights after week 25 of DMBA administration.<sup>1</sup>

Group/ Treatment <sup>2</sup>	Effective number of rats <sup>3</sup>	Final body-weight (g)	Body-weight gain (g)	Organs relative weight <sup>4</sup> (%)		
				R. Ovary	L. Ovary	Uterus
G1 DMBA	12/8	318.33 ± 91.89 <sup>a</sup>	137.67 ± 39.74	0.06 ± 0.02	0.06 ± 0.02	0.99 ± 0.29
G2 500 ppm +DMBA	12/12	327.92 ± 94.66 <sup>a</sup>	147.33 ± 2.53	0.06 ± 0.02	0.06 ± 0.02	0.70 ± 0.21
G3 750 ppm +DMBA	12/9	313.00 ± 90.36 <sup>a</sup>	139.25 ± 40.20	0.06 ± 0.02	0.06 ± 0.02	0.96 ± 0.28
G4 1250 ppm +DMBA	12/8	294.67 ± 85.06 <sup>b</sup>	134.17 ± 38.73	0.06 ± 0.02	0.07 ± 0.02	0.72 ± 0.21

<sup>1</sup>Values are mean ± S.E.M.; <sup>2</sup>DMBA = (7,12-dimethylbenz(a)anthracene, 50 mg/kg i.g.) plus 500, 750 or 1250 ppm of Diuron in basal diet. <sup>3</sup> (51 DPN to the 25<sup>th</sup> week of the experiment). <sup>4</sup>R= Right. L= Left.

Table 5 – Data from mammary tumor analysis in DMBA-initiated groups obtained during experimental period.

	Group/Treatment <sup>1</sup>			
	G1	G2	G3	G4
	DMBA	500 ppm +DMBA	750 ppm +DMBA	1250 ppm +DMBA
Effective number of rats <sup>2</sup>	12/08	12/12	12/09	12/08
Period of first tumor appearance (days)	86.80 ± 38.82	119.00 ± 84.15	99.40 ± 44.45	96.60 ± 43.20
Day of 1 <sup>st</sup> tumor	35°	105°	56°	63°
Incidence of tumor bearing rats (%)	08 (67)	04 (33)	07 (58)	07 (58)
Multiplicity <sup>3</sup> (No./rat)	1.63 ± 0.57	2.00 ± 1.15	1.43 ± 0.54	1.14 ± 0.43
Tumor weight (g)	16.25 ± 6.64	8.51 ± 6.02	11.03 ± 4.50	10.61 ± 4.75
Histological Types	10 <sup>4</sup>	6	9	8
Fibroma (%)	2 (20)	1 (17)	0	2 (25)
Adenocarcinoma (%)	8 (80)	5 (83)	9 (100)	6 (75)

<sup>1</sup>DMBA = (7,12-dimethylbenz(a)anthracene, 50 mg/kg i.g.) plus 500, 750 or 1200 ppm of Diuron in basal diet.;

<sup>2</sup>Number of animals in beginning and end of experiment; <sup>3</sup>Multiplicity: average number of tumors/tumor-bearing rat. <sup>4</sup>Total number of mammary tumors. No significant different was observed among groups.



## *Conclusões Gerais*

## Conclusões Gerais

A partir dos resultados obtidos e sob as condições experimentais empregadas no presente trabalho, podemos concluir que:

1. O herbicida Diuron não apresenta atividade promotora da carcinogênese mamária em fêmeas SD adultas. A incidência, tipos e multiplicidade das neoplasias mamárias induzidas pela DMBA não foram alteradas pela exposição ao Diuron durante a fase de pós-iniciação da carcinogênese mamária.
2. Os níveis de expressão imunoistoquímica do RE alpha, p63, anti-bcl-2, anti-bak e PCNA não foram modificados em decorrência do tratamento crônico com o herbicida Diuron.
3. O tratamento com o herbicida Diuron nas fases gestacional, lactacional e juvenil não alterou o dia da abertura vaginal, indicando ausência de efeitos adversos sobre o início da puberdade.
4. O tratamento com o herbicida Diuron nas fases gestacional, lactacional e juvenil não alterou o ciclo estral e a espessura da camada epitelial do

endométrio, indicando a capacidade de resposta hormonal normal do aparelho reprodutivo feminino de fêmeas SD previamente expostas ao Diuron.

5. As alterações observadas nos ovários poderiam ser consideradas um indicativo de toxicidade no sistema reprodutor feminino, mas o impacto da exposição sobre a morfologia do ovário e função requer estudos complementares.

6. A exposição ao herbicida Diuron durante o período crítico de desenvolvimento da glândula mamária, não alterou o desenvolvimento (atrofia) ou induziu hiperplasia túbulo-alveolar nem alterou os níveis séricos de progesterona e estradiol, considerados biomarcadores de efeitos de desregulação endócrina.

7. O tratamento com o herbicida Diuron não alterou a cinética de proliferação celular, apoptose e imunoreatividade para receptor de estrógeno no epitélio ductal e alveolar das glândulas mamárias, indicando que a exposição precoce ao herbicida Diuron não induz perturbação no sistema hormonal ou danos mamários.

8. A exposição precoce ao herbicida Diuron não modificou o desenvolvimento estrutural ou neoplásico da glândula mamária na prole de fêmeas adulta Sprague-Dawley.

9. Estudos complementares devem ser conduzidos utilizando-se a linhagem de camundongos NMR1 em exposição a altas concentrações do herbicida Diuron para o melhor entendimento do modo de ação na glândula mamária e das possíveis atividades carcinogênicas espécie-específica visto que Moura *et al.* 2009 não observaram efeitos carcinogênicos na glândula mamária de camundongos da linhagem Swiss quando expostos a altas concentrações de Diuron. (*ver anexo*)



*Anexos*

## Potential effects of the herbicide Diuron on mammary and urinary bladder two-stage carcinogenesis in a female Swiss mouse model

Nelci Antunes de Moura · Tony Fernando Grassi ·  
Maria Aparecida Marchesan Rodrigues ·  
Luís Fernando Barbisan

Received: 17 July 2009 / Accepted: 8 October 2009  
© Springer-Verlag 2009

**Abstract** The potential promoting effect of Diuron was investigated in a mouse model of mammary and urinary bladder carcinogenesis induced by 7,12-dimethylbenz(a)anthracene (DMBA) and *N*-butyl-*N*-(4-hydroxybutyl)nitrosamine (BBN). Four-week old female Swiss mice were allocated to five groups: Groups G1-G3 received DMBA ( $5 \times 1.5$  mg/mouse) and BBN ( $8 \times 7.5$  mg/mouse) and G4 and G5 groups received only vehicles during the first 6 weeks. At week 7, G1 and G5 groups received basal diet and G2, G3 and G4 groups were fed a diet containing Diuron at 1,250, 2,500 and 2,500 ppm, respectively, during 13 weeks. At week 20, the animals were euthanized and the gross tumors were registered. Mammary glands and urinary bladder were processed for histopathological analysis. Samples from non-tumor areas were evaluated for cell proliferation by 5-bromodeoxyuridine labeling index (BrdU-LI%) and apoptosis. Dietary treatment with Diuron at 1,250 and 2,500 ppm significantly increased BrdU-LI% ( $P < 0.05$ ) and the incidence of simple/nodular urothelial hyperplasia in the urinary bladder from DMBA/BBN-initiated groups (G2 and G3 vs. G1,  $P < 0.02$ ) and in the non-initiated group (G4 vs. G5,  $P = 0.042$ ). Two transitional cell carcinomas were observed in the group initiated and fed Diuron 2,500 ppm (G3). In contrast, in the mammary gland, Diuron feeding for 13 weeks did not significantly alter cell proliferation and apoptosis indexes or the incidence

of hyperplastic lesions or neoplasms in the DMBA/BBN-initiated groups. These findings suggest that Diuron is a promoting agent to the urinary bladder but not to the mammary gland in female Swiss mice submitted to a medium-term two-stage carcinogenesis bioassay.

**Keywords** Pesticides · Diuron · Mammary and urinary bladder carcinogenesis · Female Swiss mouse

### Introduction

Diuron [3-(3,4-dichlorophenyl)-1-1-dimethylurea], a substituted phenyl urea herbicide has been used throughout the world to control a wide variety of annual and perennial broadleaf and grassy weeds on both crop (i.e., citrus fruit, cotton, asparagus, sugar cane, alfalfa, wheat and grapes) and non-crop sites (i.e., roads, garden paths and railways) (Iyer 2002; Field et al. 2003; Giacomazzi and Cochet 2004). In Brazil, it has been widely employed in the cultivation of sugar cane (Nascimento et al. 2006). Diuron *per se* has low systemic toxicity to mammals and birds, and moderate toxicity to aquatic invertebrates. This herbicide is biotransformed in the liver microsomes from human, rat and mouse and the urine is the primary route of excretion for Diuron and its metabolites (Verheij et al. 1989; Van Boven et al. 1990; Giacomazzi and Cochet 2004; Abass et al. 2007). Its principal biodegradation product, 3-4-dichloroaniline (3-DCA), is highly toxic and relatively persistent in the environment (Iyer 2002; Giacomazzi and Cochet 2004). Due to the high persistence in the soil, water and groundwater, contamination by this herbicide may represent an important public health problem.

In the absence of convincing epidemiological evidences, but taking into account that Diuron has been shown to be

N. A. de Moura · L. F. Barbisan (✉)  
Department of Morphology, UNESP São Paulo State University,  
Institute of Biosciences, Botucatu, SP 18618-000, Brazil  
e-mail: barbisn@ibb.unesp.br

T. F. Grassi · M. A. M. Rodrigues · L. F. Barbisan  
Faculty of Medicine, Department of Pathology,  
UNESP São Paulo State University, Botucatu, SP, Brazil

carcinogenic to rodents, the United States Environmental Protection Agency (US EPA) considered Diuron as a “known/likely” carcinogen to humans (U.S. EPA 2003, 2004). In a 2-year feeding study, male and female Wistar rats exposed to Diuron at 2,500 ppm presented increased incidences of urinary bladder and renal pelvis tumors (Iyer 2002). Besides, female NMRI mice chronically exposed to Diuron at 2,500 ppm developed an increased incidence of mammary adenocarcinomas (Iyer 2002). Also, we have recently demonstrated that 20-week dietary treatment with Diuron at 2,500 ppm is associated with urothelial necrosis and continuous regenerative cell proliferation in male Wistar rats, resulting in the development of urothelial hyperplasia (Nascimento et al. 2006).

The most widely used carcinogens in medium-term bioassay for mammary and urinary bladder carcinogenesis are 7-12-dimethylbenz(a)anthracene (DMBA) and *N*-butyl-*N*-(4-hydroxybutyl)nitrosamine (BBN), respectively (Fischer et al. 1992; Qing et al. 1997; Cohen 1998, 2002). Treatment of female mice with DMBA induces the development of hyperplastic lesions like alveolar/ductal hyperplasia, benign tumors such as adenoma, fibroma, fibroadenoma and malignant neoplasms like adenocarcinomas similar to those seen in humans (Fischer et al. 1992; Qing et al. 1997; Cardiff and Wellings 1999). Moreover, treatment of male and female mice with BBN produces urinary bladder tumors that strongly resemble human high-grade invasive urothelial neoplasia. In BBN-treated mice, urothelial carcinogenesis proceeds through a sequence of morphologic changes: simple hyperplasia that becomes nodular and/or papillary hyperplasia (the first is more common), and then progression to invasive urothelial carcinomas (Cohen 1998, 2002).

Since Diuron did not present a convincing carcinogenic activity to the urinary bladder and mammary gland of non-initiated female NMRI mice, the present study was conducted to assess the potential promoting effects of the herbicide Diuron on mammary and urinary bladder carcinogenesis initiated by DMBA/BBN in a medium-term two-stage bioassay in female Swiss mice. This mouse multi-organ model was established to detect the possible enhancing influence of Diuron in a single experiment of carcinogenesis. In addition, the effects of Diuron on cell proliferation, as estimated by nuclear incorporation of 5-bromodeoxyuridine (BrdU), and apoptosis were also examined.

## Materials and methods

### Chemicals

7,12-Dimethylbenz(a)anthracene (DMBA, CAS 57-97-6) and 3-(3,4-dichlorophenyl)-1-1-dimethylurea (Diuron, CAS 30-54-1, analytical standard grade) were purchased

from Sigma–Aldrich Co. (St. Louis, MO, USA) and *N*-butyl-*N*-(4-hydroxybutyl)nitrosamine (BBN) was purchased from Tokyo Kasei Industries Co. (Tokyo, Japan).

### Experimental design

The University Committee for Ethics in Animal Research approved the protocol used in this study (Protocol number 78/07). Female 3-week-old Swiss mice were obtained from the Multidisciplinary Center for Biological Investigation (CEMIB/UNICAMP Campinas-SP, Brazil). The animals were housed in polypropylene cages covered with metallic grill in a room maintained at  $22 \pm 2^\circ\text{C}$ ,  $55 \pm 10\%$  humidity and a 12 h light/dark cycle. They were fed commercial Purina chow (Paulínia, SP, Brazil) and water ad libitum for a 1-week acclimatization period.


Mice were randomly allocated into five groups, consisting of 15 animals (Fig. 1). Groups G1 to G3 were given intragastric administration (i.g.) of DMBA ( $5 \times 1.5$  mg/mouse) and BBN ( $8 \times 7.5$  mg/mouse) and G4 and G5 groups received only the vehicle Canola oil and ethanol:water (20:80) (i.e., DMBA and BBN vehicles, respectively) during the first six weeks. This experimental design using DMBA to initiate mammary carcinogenesis and BBN to initiate urinary bladder carcinogenesis was adapted from previously described protocols (Rao et al. 1996; Quin et al. 1997). At week 7, G1 and G5 groups were fed basal diet and G2, G3, G4 groups received basal diet containing Diuron at 1,250, 2,500 or 2,500 ppm, respectively, for 13 weeks. The higher dietary concentration of Diuron was chosen due to the carcinogenic potential detected in chronic feeding studies in Wistar rats and NMRI mice (Iyer 2002).

During the experimental period, the mice were carefully checked for the presence of gross mammary tumors once a week and data on the number and localization of each palpable mass in the different mammary gland complexes were recorded. All animals were euthanatized by exsanguination under sodium pentobarbital anesthesia (45 mg/kg b.w.). Individual body weights and food consumption were recorded weekly during the experimental period. Two hours before sacrifice, mice were administered a single i.p. injection of 100 mg/kg b.w. of bromodeoxyuridine (BrdU) (Sigma–Aldrich Co.) between 8:00 and 11:00 AM.

### Tissue processing, histology and immunohistochemical procedures

At necropsy, the whole skin with mammary glands and tumors, liver, kidneys, spleen, and urinary bladder were removed and fixed in 10% phosphate-buffered formalin for 24 h. Before fixation, liver, kidneys and spleen were weighed. Each urinary bladder was cut into 4–6 strips. Samples of selected organs were processed for paraffin

**Fig. 1** Experimental design. DMBA = 7,12-dimethylbenz(a)anthracene and BBN = *N*-butyl-*N*-(4-hydroxybutyl). See details in “Material and methods”



embedding and stained with hematoxylin-eosin (HE) for histopathological and immunohistochemical analysis. Mammary lesions were classified as alveolar/ductal hyperplasia, in situ carcinoma, adenocarcinoma and acanthoma and urothelial lesions were classified as simple or nodular hyperplasia and transitional cell carcinoma (TCC) according to previously published criteria (Cardiff and Wellings 1999; Cohen 1998, 2002).


After deparaffinization, 5- $\mu$ m-thick sections on poly-L-lysine coated slides were sequentially incubated with 2N HCl for 30 min at 37°C and 0.025% trypsin (Sigma-Aldrich, USA) for 10 min, 3%  $H_2O_2$  in phosphate-buffered saline (PBS) for 15 min in dark and 1% non-fat milk in PBS for 60 min at room temperature. Sections were overnight incubated at 4°C with a mixture containing primary antibody mouse monoclonal anti-BrdU/Clone BU33 (Sigma Co. St. Louis, MO, USA), biotinylated secondary antibody horse anti-mouse (Vector Laboratories, Inc., Burlingame, CA, USA) and normal serum mouse at final concentration 1:100/1:200/1:2,400, respectively (Fung et al. 1992). Then, the slides were incubated with streptavidin-biotin-peroxidase solution (TissuGnost Kit Merck, Darmstadt, Germany, 1:1:50 dilution) for 45 min at room temperature. Chromogen color development was accomplished with 3,3'-diam-

inobenzidine tetrahydrochloride (DAB, Sigma-Aldrich Co.) as the substrate to demonstrate the sites of peroxidase binding (brown nuclear staining). The slides were counterstained with Harris's hematoxylin. A segment of the small intestine from each animal was included to confirm nuclear incorporation of BrdU and a negative control was performed in all cases by omitting incubation with the primary antibody for BrdU, which in all instances resulted in negative immunoreactivity.

#### BrdU-labeling index and apoptosis analysis

BrdU labeling (BrdU-LI%) and apoptotic (AI%) indexes in mammary glands and urinary bladder epithelium were determined by dividing the number of cells positive for BrdU or in apoptosis (Fig. 2), respectively, by the total number of cells scored and multiplying by 100. The morphological criteria for the apoptotic cells identification was used as previously described (Levin et al. 1999). Approximately, 350–500 mammary epithelial cells and 1,000 urothelial cells in microscopic fields were scored under a 40 $\times$  objective. Non-altered (non-initiated groups, G4 and G5) and non-altered and hyperplastic areas (initiated groups, G1 to G3), but not tumors, were randomly analyzed in mammary glands and urinary bladder urothelium.

**Fig. 2** Bromodeoxyuridine-labeling cells (dark nuclei in immunohistochemically stained sections, *black arrow*.) and apoptotic cells (*white arrows*, in HE stained section) in bladder urothelium (a and b) and mammary glands (c and d) from DMBA/BBN-initiated or non-initiated mice groups. **a** BrdU-positive urothelial cells, non-initiated/Diuron-treated 2,500 ppm mouse (G4 group); **b** Apoptosis in urothelial cell, non-initiated/Diuron-treated 2,500 ppm mouse (G4 group); **c** BrdU-positive mammary alveolar cells, DMBA/BBN-initiated mouse (G1 group); **d** Apoptosis in mammary alveolar cells, DMBA/BBN-initiated/Diuron-treated 1,250 ppm mouse (G2 group)



### Statistical analysis

Data for body weight and body-weight gain, food consumption, relative liver, kidney and spleen weights were analyzed by the ANOVA or Student T tests when the results presenting normal distribution or Kruskal–Wallis or Mann–Whitney tests when this did not occur. The contrast among groups for ANOVA or Kruskal–Wallis tests was analyzed by the Tukey or Student–Newman–Keuls methods. Incidences of preneoplastic lesions or neoplasms were examined using the chi-squared or the Fischer tests. Significant differences were assumed when  $P < 0.05$ . The statistical analyses were performed using the Jandel Sigma Stat software (Jandel Corporation, San Rafael, CA, USA).

### Results

#### Mortality, body and organ weights and food consumption

At the end of the experimental period, survival rates were 93.3% in DMBA/BBN-initiated group (G1), 73.3% in both DMBA/BBN-initiated/Diuron-treated 1,250 and 2,500 ppm groups (G2 and G3, respectively) and 100% in both non-initiated/Diuron-treated 2,500 ppm and control groups (G4 and G5, respectively). A complete necropsy was not carried out on dead mice due to the advanced postmortem changes. The presumed cause of death was probably related to the

induction of lymphomas by multiple doses of DMBA (Qing et al. 1997; Buters et al. 1999).

Food consumption, body-weight gain and final body weight were not significantly altered in DMBA/BBN-initiated/Diuron-treated 1,250 and 2,500 ppm groups (G2 and G3) or in non-initiated/Diuron-treated 2,500 ppm group (G4) when compared to the respective control groups (G1 and G5, respectively) (Table 1). At week 20, an increase in relative liver ( $P < 0.05$ ) and spleen ( $P < 0.005$ ) weights were simultaneously observed in DMBA/BBN-initiated/Diuron-treated 2,500 ppm group (G3) and in non-initiated-Diuron-treated 2,500 ppm group (G4) (Table 2). Diuron feeding did not cause any significant alteration in relative weights of right or left kidney compared to the respective controls (Table 2).

#### Histopathologic and immunohistochemical analysis

Some female Swiss mice exposed to Diuron at 2,500 ppm (G3 and G4 groups) developed hepatic centrilobular hypertrophy and splenomegaly characterized by congestion, extramedullary hemocytopenia and hemosiderosis. These changes in the liver and spleen were related to toxicity of high doses of Diuron as previously described by our group in male Wistar rats (Nascimento et al. 2006; Grassi et al. 2007; Fernandes et al. 2007). Also, female Swiss mice exposed to Diuron at 2,500 ppm developed simple and nodular hyperplasia in renal pelvis but no tumor was detected in non-initiated or initiated groups.

**Table 1** Body weight data, water and food and Diuron intake values in the different experimental groups

Group/treatment	Number of mice	Body weight (g)			Consumption		
		Initial	Final	Gain	Water (ml/mouse day)	Food (g/mouse day)	Diuron (mg/mouse day)
Initiated							
(G1) DMBA/BBN	14	21.33 ± 2.50	46.71 ± 5.95	25.14 ± 7.26	6.58 ± 0.82	6.17 ± 1.43	–
(G2) DMBA/BBN + 1,250 ppm	11	21.66 ± 3.33	42.18 ± 7.4	21.09 ± 5.6	6.20 ± 0.86	6.19 ± 1.44	85.61 ± 9.36
(G3) DMBA/BBN + 2,500 ppm	11	22.20 ± 3.34	40.90 ± 4.72	19.45 ± 4.84	6.50 ± 0.73	6.09 ± 1.10	142.29 ± 18.59
Non-initiated							
(G4) 2,500 ppm	15	21.61 ± 1.90	46.68 ± 5.0	24.33 ± 5.1	6.74 ± 0.75	6.82 ± 1.44	159.66 ± 11.36
(G5) Control	15	22.46 ± 2.70	50.0 ± 4.67	27.54 ± 5.5	6.85 ± 0.46	6.86 ± 1.07	–

Values are mean ± SD

*DMBA* 7,12-dimethylbenz(a)anthracene (4 × 1.5 mg/mouse, i.g.); *BBN* *N*-butyl-*N*-(4-hydroxybutyl)nitrosamine (8 × 7.5 mg/mouse, i.g.); 1,250 or 2,500 ppm of Diuron in the basal diet for 13 weeks

**Table 2** Relative weights values of liver, spleen and kidney in the different experimental groups

Group/treatment	Number of mice	Relative weight organs (%)			
		Liver	Spleen	Right kidney	Left kidney
Initiated					
(G1) DMBA/BBN	14	4.20 ± 0.55	0.24 ± 0.68	0.48 ± 0.06	0.47 ± 0.10
(G2) DMBA/BBN + 1,250 ppm	11	4.16 ± 0.45	0.32 ± 0.96	0.50 ± 0.09	0.49 ± 0.09
(G3) DMBA/BBN + 2,500 ppm	10	4.93 ± 0.67 <sup>a*</sup>	0.42 ± 0.12 <sup>b*</sup>	0.50 ± 0.08	0.52 ± 0.13
Non-initiated					
(G4) 2,500 ppm	14	3.87 ± 0.32 <sup>a**</sup>	0.29 ± 0.07 <sup>b**</sup>	0.47 ± 0.05	0.48 ± 0.06
(G5) Control	15	3.52 ± 0.49	0.22 ± 0.05	0.45 ± 0.08	0.45 ± 0.06

Values are mean ± SD

*DMBA* 7,12-dimethylbenz(a)anthracene (4 × 1.5 mg/mouse, i.g.); *BBN* *N*-butyl-*N*-(4-hydroxybutyl)nitrosamine (8 × 7.5 mg/mouse, i.g.); 1,250 or 2,500 ppm of Diuron in the basal diet for 13 weeks

<sup>a,b</sup> Different from G1 or G5 groups, respectively, \*  $P < 0.05$ , \*\*  $P < 0.005$

The modifying effects of Diuron on the incidence of pre-neoplastic and neoplastic lesions in the mammary gland and urinary bladder are shown in Table 3. The DMBA/BBN-initiated mice developed preneoplastic (i.e., ductal or alveolar hyperplasia) and neoplastic (i.e., adenocarcinomas/acanthoma) lesions in the mammary gland at the end of week 20 (Fig. 3). Mammary tumors were histologically classified as adenocarcinomas (Fig. 3e) or with squamous areas (acanthomas). In general, DMBA-induced tumors were non-metastatic but frequently presented an invasive pattern. Diuron feeding for 13-week did not significantly alter the incidence or burden of hyperplastic lesions or neoplasms in the mammary gland from DMBA/BBN-initiated mice. Also, no preneoplastic or neoplastic lesions were observed in the mammary glands from non-initiated/Diuron treated 2,500 ppm (G5 group).

In the urinary bladder, Diuron feeding at 1,250 and 2,500 ppm resulted in a significant increase in the incidence

of simple/nodular urothelial hyperplasia (Fig. 2) in both DMBA/BBN-initiated (G2 and G3 vs. G1,  $P < 0.02$ ) and non-initiated groups (G5 vs. G4,  $P = 0.042$ ) (Table 3). Two invasive transitional cell carcinomas were observed in DMBA/BBN-initiated/Diuron treated 2,500 ppm group (G3). Non-initiated/Diuron-treated 2,500 ppm mice developed only simple hyperplasia.

The rates of BrdU-labeling (BrdU-LI%) and apoptosis (AI%) in the mammary gland and bladder urothelium are shown in Fig. 4. In the mammary gland, the rates of cell proliferation and apoptosis did not differ among initiated or non-initiated groups after 13-weeks Diuron feeding. In contrast in the urinary bladder, Diuron feeding induced a significant increase in urothelial BrdU-LI%, but not in AI%, in both initiated (G2 and G3) and non-initiated groups (G4) when compared to the respective control groups (G1 and G5) ( $P < 0.042$  and  $P < 0.020$ , respectively).

**Table 3** Incidence (%) of mammary and urothelial preneoplastic and neoplastic lesions in the different experimental groups

Group/treatment	Number of mice	Mammary lesions		Urothelial lesions	
		DH/AH	ADENOCAR	SH/NH (%)	TCC
Initiated					
(G1) DMBA/BBN	14	6 (43%)	5 (36%)	8 (57)	0
(G2) DMBA/BBN + 1,250 ppm	11	5 (45%)	7 (64%)	11 (100)**	0
(G3) DMBA/BBN + 2,500 ppm	11	3 (27%)	7 (64%)	11 (100)**	2 (18%)
Non-initiated					
(G4) 2,500 ppm	15	0	0	5 (33) <sup>b**</sup>	0
(G5) Control	15	0	0	0 (0)	0

DMBA 7,12-dimethylbenz(a)anthracene ( $5 \times 1.5$  mg/mouse, i.g.); BBN *N*-butyl-*N*-(4-hydroxybutyl)nitrosamine ( $8 \times 7.5$  mg/mouse, i.g.), 1,250 or 2,500 ppm of Diuron in the basal diet for 12 weeks; DH/AH ductal hyperplasia or alveolar hyperplasia; ADENOCAR adenocarcinoma;

SH/NH simple hyperplasia or nodular hyperplasia; TCC transitional cell carcinoma

<sup>a,b</sup> Different from G1 or G5 groups, respectively, \*  $P < 0.02$ , \*\*  $P < 0.042$

## Discussion

In the present study sub-chronic treatment with Diuron at high concentrations did not modify mammary carcinogenesis but enhanced tumorigenesis in the urinary bladder from DMBA/BBN-initiated female Swiss mice. These findings were obtained using dietary concentrations of Diuron known to have carcinogenic potential to urinary bladder in both genders of Wistar rats and NMRI mice and mammary gland of female NMRI mice in a long-term feeding study (Iyer 2002, U.S. EPA 2003).

Female NMRI mice exposed for 12 months to Diuron at 2,500 ppm developed a low incidence of mammary adenocarcinomas. The incidence of these neoplasms were 2/50, 1/47, 1/49 and 6/50 in the groups fed Diuron at 0, 25, 250, and 2,500 ppm, respectively (Iyer 2002). Therefore, the occurrence of mammary tumors in this murine model of exposure to Diuron may be considered “spontaneous” and no significant effects on the reproductive system have been described (U.S. EPA 2003). In the present study, treatment with Diuron at 2,500 ppm for 13-weeks did not alter the rates BrdU-labeling or apoptosis in the mammary gland neither had a promoting effect on mammary gland carcinogenesis in female Swiss mice initiated with DMBA. These findings are not conflicting with previous results in female NMRI mice carcinogenic study since this later study was not conclusive and were based on a statistical trend of mammary tumors of spontaneous occurrence.


Some pesticides with potential endocrine disrupting properties have been categorized as mammary carcinogens in rodent studies (Ueda et al. 2005; Rudel et al. 2007). These pesticides, including some substituted urea herbicides, are able to block or inactivate the steroid hormone receptors and/or affect the levels of sex hormones with potential to affecting the development and function of the male and female reproductive system (Cook et al. 1993;

Bauer et al. 1998; Vinggaard et al. 1999, 2000; Kojima et al. 2004; Noguerol et al. 2006). Findings from in vitro assays indicate that Diuron has the capacity to connect to the androgen receptor, thus allowing this herbicide to act as an endocrine disruptor, as the herbicide linuron, a related substituted urea compound (Cook et al. 1993; Bauer et al. 1998). Diuron did not affect CYP19 aromatase activity in the human placental microsomes assay, indicating that this herbicide did not interfere in the conversion of androgens to estrogens, which could alter the balance between male and female sex hormones (Vinggaard et al. 2000). In a recent study in California with breast cancer bearing women living in areas of recent and high agricultural pesticides use, Diuron was selected for individual analysis as a potential xenoestrogenic carcinogen (Reynolds et al. 2005). However, in vitro assays indicated that this herbicide did not appear to show estrogen receptor (ER)-mediated response using human MCF-7 breast cancer cells, Chinese hamster ovary cells or recombinant yeast strains (Vinggaard et al. 1999; Kojima et al. 2004; Noguerol et al. 2006). These in vitro results are in keeping with our findings on the absence of promoting effects of Diuron on mammary carcinogenesis, thus indicating that mammary gland is not a potential target organ for the carcinogenic effect of this herbicide.

In the urinary bladder, long-term treatment with Diuron at 2,500 ppm induced the development of papillomas and carcinomas in both male and female Wistar rats (Iyer 2002). The incidence of these tumors in the urinary bladder were 1/49, 0/50, 1/49 and 35/48 in male and 1/47, 0/49, 1/50 and 13/49 in female rats exposed to Diuron at concentrations of 0, 25, 250, and 2,500 ppm, respectively. Moreover, an increase in hyperplasia in the urinary bladder was observed in female NMRI mice exposed to Diuron at 2,500 ppm for 24 months (Iyer 2002). In the present study, treatment with Diuron at 2,500 ppm for 13-week resulted in a significant increase in the incidence of simple/nodular

**Fig. 3** Representative microscopic lesions in urinary bladder (a–d) and mammary gland (e and f) of DMBA/BBN-initiated or non-initiated mice groups.

**a** Normal urothelium, non-initiated mouse (G5 group); **b** Simple hyperplasia, DMBA/BBN-initiated mouse (G1 group); **c** Nodular hyperplasia, DMBA/BBN-initiated/Diuron treated 1,250 ppm mouse (G2 group); **d** Transitional cell carcinoma, DMBA/BBN-initiated/Diuron-treated 2,500 ppm mouse; **e** Alveolar mammary hyperplasia, DMBA/BBN-initiated mouse (G1 group). Hyperplastic alveoli (arrowheads) and non-altered alveolus (arrow); **f** Mammary adenocarcinoma, DMBA/BBN-initiated/Diuron-treated 2,500 ppm mouse (G3 group)




hyperplasia in the urinary bladder from both DMBA/BBN-initiated or non-initiated groups. These lesions are a predisposing condition to urinary bladder carcinogenesis in rodents and considered as early precursors of papilloma and transitional invasive urothelial carcinomas (Cohen 1998, 2002).

Increased urothelial cell proliferation can occur by cytotoxicity and regeneration (Cohen 1998). Diuron feeding at high concentrations to male Wistar rats does not induce urothelial DNA damage, but increases cell necrosis and regenerative cell proliferation that leads to urothelial hyperplasia (Nascimento et al. 2006). Although some evidence of mutagenic potential have been observed in Swiss mice submitted to the bone marrow micronucleus assay and in the dominant lethal test, Diuron was negative in most *in vitro* and *in vivo* genetic toxicology assays (Liu 2002; Iyer 2002;

U.S. EPA 2003). Thus, the most probable mode of carcinogenic action (MOA) of Diuron on the urinary bladder urothelium in male Wistar rats may be as a non-genotoxic pathway associated to persistent cytotoxicity and regenerative proliferation (Nascimento et al. 2006).

In rodent studies with genotoxic agents, such as 4-aminobiphenyl, 2-acetylaminofluorene and cyclophosphamide, an increased incidence of bladder tumors was detected only at doses at which there was a relationship between DNA damage and increased urothelial cell proliferation (Cohen and Ellwein 1990; Cohen et al. 2006; McCarroll et al. 2008). On the other hand, non-genotoxic agents can induce the development of hyperplastic lesions and bladder tumors through continuous stimulation of urothelial cell proliferation (Cohen 1998). In the present study, a significant increase in BrdU-labeling index was observed



**Fig. 4** Effects of Diuron on cell proliferation and apoptosis in the mammary gland and urinary bladder from initiated and non-initiated groups. BrdU LI% = bromodeoxyuridine-labeling indexes; AI (%) = Apoptosis indexes. \*,\*\* Significantly different from G1 or G5 groups,  $P < 0.01$  and  $P < 0.05$ , respectively

in either non-initiated or initiated female Swiss mice fed Diuron at 2,500 ppm. Regenerative urothelial cell proliferation secondary to cytotoxicity can be produced by the presence of urinary solids such as precipitates, microcrystals, or calculi (Cohen 1998). In a previous study, magnesium ammonium phosphate crystals and urothelial cytotoxicity was detected by SEM in male Wistar rats exposed to Diuron 2,500 ppm, but the cause of urothelial necrosis was not completely determined (Nascimento et al. 2006). In this way, diffuse necrosis with consequent regenerative hyperplasia in the absence of a clear genotoxic potential could be considered as the MOA of Diuron at high doses on rodent urinary bladder tumorigenesis, as detected in standard feeding long-term bioassays (Iyer 2002).

Using a cytotoxic MOA as a paradigm for urinary bladder carcinogenesis, the sustained cytotoxicity and regenerative cell proliferation could be considered relevant for evaluating human cancer risk, if metabolic and oncogenic pathways are common to animal models and in humans (Cohen et al. 2004, 2006). This persistent urothelial cytotoxicity could be related to reactive metabolites in urine, generated during mouse hepatic Diuron *N*-demethylation (Abass et al. 2007), leading to development of hyperplasia and ultimately in tumors. As Diuron has been reported to be biotransformed by in vitro and in vivo human cytochrome

(CYP) P450s (Abass et al. 2007), a possible cytotoxic MOA could be operative for humans exposed to larger amounts of Diuron and that present a high CYP1A2 content, which may be able to metabolize Diuron more efficiently (Abass et al. 2007).

3,4-dichloroaniline (3,4-DCA) is an intermediate in the industrial production of various substituted phenyl urea herbicides, including Diuron (Giacomazi and Cochet 2004). The 3,4-DCA is a major metabolite of Diuron frequently detected in urine from human exposed to substituted phenyl urea herbicides (Verheij et al. 1989; Van Boven et al. 1990; Nguyen et al. 2007). Valentovic et al. (1997) have described early toxic effects of 3,4-DCA on liver, kidney and urinary bladder of male F344 rats. Thus, urothelial toxicity by Diuron metabolites present in urine could contribute to urinary bladder carcinogenesis in non-initiated and initiated female Swiss mice.


In conclusion, the results of present study indicate that Diuron at high concentrations enhanced tumor development in the urinary bladder, but not in the mammary gland in a murine model of carcinogenesis. As there is no report of human tumors related to exposure to Diuron, the characterization of a carcinogenic mode of action of Diuron and its biological plausibility to exposed humans should continue to be investigated.

**Acknowledgments** We acknowledge Prof. Dr. João Lauro Viana de Camargo (Botucatu School of Medicine, UNESP) for scientific discussion and useful advice. This study was supported by FAPESP (State of São Paulo Research Foundation) and TOXICAM (Centre of the Evaluation of the Impact of the Environment on Human Health from Department of Pathology—Botucatu Medical School, UNESP, Brazil). De Moura, N. A and Grassi, T. F were recipient of a fellowship from FAPESP (2007/58937-7 and 2006/01330-0, respectively).


## References

- Abass K, Reponen P, Turpeinen M, Jalonen J, Pelkonen O (2007) Characterization of Diuron *N*-demethylation by mammalian hepatic microsomes and cDNA-expressed human cytochrome P450 enzymes. *Drug Metab Dispos* 35:1634–1641
- Bauer ER, Meyer HH, Stahlschmidt-Allner P, Sauerwein H (1998) Application of an androgen receptor assay for the characterization of the androgenic or antiandrogenic activity of various phenylurea herbicides and their derivatives. *Analyst* 123:2485–2487
- Buters JT, Sakai S, Richter T, Pineau T, Alexander DL, Savas U, Doehmer J, Ward JM, Jefcoate CR, Gonzalez FJ (1999) Cytochrome P450 CYP1B1 determines susceptibility to 7, 12-dimethylbenz[a]anthracene-induced lymphomas. *Proc Natl Acad Sci USA* 96:1977–1982
- Cardiff RD, Wellings SR (1999) The comparative pathology of human and mouse mammary glands. *J Mammary Gland Biol Neoplasia* 4:105–122
- Cohen SM (1998) Urinary bladder carcinogenesis. *Toxicol Pathol* 26:121–127
- Cohen SM (2002) Comparative pathology of proliferative lesions of the urinary bladder. *Toxicol Pathol* 30:663–671

- Cohen SM, Ellwein LB (1990) Proliferative and genotoxic cellular effects in 2 acetylaminofluorene bladder and liver carcinogenesis: biological modeling of the ED 01 study. *Toxicol Appl Pharmacol* 104:79–93
- Cohen SM, Klauning J, Meek ME, Hill RN, Pastoor T, Lehman-McKeeman L, Bucher J, Longfellow DG, Seed J, Dellarco V, Fenner-Crisp P, Phanton D (2004) Evaluating the human relevance of chemically-induced animal tumors. *Toxicol Sci* 78:181–186
- Cohen SM, Boobis AR, Meek ME, Preston RJ, McGregor DB (2006) 4-Aminobiphenyl and DNA reactivity: case study within the context of the IPCS human relevance framework for analysis of a cancer mode of action for humans. *Crit Rev Toxicol* 36:803–819
- Cook JC, Mullin LS, Frame SR, Biegel LB (1993) Investigation of a mechanism for Leydig cell tumorigenesis by linuron in rats. *Toxicol Appl Pharmacol* 19:195–204
- Fernandes GS, Arena AC, Fernandez CD, Mercadante A, Barbisan LF, Kempinas WG (2007) Reproductive effects in male rats exposed to diuron. *Reprod Toxicol* 23:106–112
- Field JA, Reed RL, Sawyer TE, Griffith SM, Wigington PJ Jr (2003) Diuron occurrence and distribution in soil and surface and ground water associated with grass seed production. *J Environ Qual* 32:171–179
- Fischer SM, Conti CJ, Locniskar M, Belury MA, Maldve RE, Lee ML, Leyton J, Slaga TJ, Bechtel DH (1992) The Effect of dietary fat on the rapid development of mammary tumors induced by 7, 12-dimethylbenz(a)anthracene in SENCAR mice. *Cancer Res* 52:662–666
- Fung KM, Messing A, Lee VMY, Trojanowski JQ (1992) A novel modification of the avidin-biotin complex method for immunohistochemical studies of transgenic mice with murine monoclonal antibodies. *J Histochem Cytochem* 40:1319–1328
- Giacomazzi S, Cochet N (2004) Environmental impact of Diuron transformation: a review. *Chemosphere* 56:1021–1032
- Grassi TF, Tararam C, Spinardi-Barbisan ALT, Camargo JLV, Barbisan LF (2007) Diuron lacks promoting potential in a rat liver bioassay. *Toxicol Pathol* 35:897–903
- Iyer P (2002) Evidence on the developmental and reproductive toxicity of Diuron reproductive and cancer hazard assessment section. Office of environmental health hazard assessment. California Environmental Protection Agency. Draft. pp 1–106
- Kojima H, Katsura E, Takeuchi S et al (2004) Screening for estrogen and androgen receptor activities in 200 pesticides in vitro reporter gene assays using Chinese Hamster ovary cells. *Environ Health Perspect* 112:524–531
- Levin S, Bucci TJ, Cohen SM, Fix AS, Hardisty JF, LeGrand EK, Maronpot RR, Trump BF (1999) The nomenclature of cell death: recommendations of an ad hoc committee of the society of toxicologic pathologists. *Toxicol Pathol* 4:484–490
- Liu J (2002) Phenylurea herbicides. In: Krieger KE (ed) *Handbook of Pesticides Toxicology Agents* Academic Press, pp 1521–1523
- McCarroll N, Keshava N, Cimino M, Chu M, Dearfield K, Keshava C, Kligerman A, Owen R, Protzel A, Putzrath R, Schoeny R (2008) An evaluation of the mode of action framework for mutagenic carcinogens case study: cyclophosphamide. *Environ Mol Mutagen* 49:117–131
- Nascimento MG, de Oliveira ML, Lima AS, de Camargo JL (2006) Effects of Diuron [3-(3, 4-dichlorophenyl)-1, 1-dimethylurea] on the urinary bladder of male Wistar rats. *Toxicology* 224:66–73
- Nguyen JV, Olsson AO, Bravo R, Needham LL, Barr DB (2007) Quantification of atrazine, phenylurea, and sulfonylurea herbicide metabolites in urine by high-performance liquid chromatography-tandem mass spectrometry. *J Anal Toxicol* 31:181–186
- Nogueroles TN, Boronat S, Casado M, Raldúa D, Barceló D, Piña B (2006) Evaluating the interactions of vertebrate receptors with persistent pollutants and antifouling pesticides using recombinant yeast assays. *Anal Bioanal Chem* 385:1012–1019
- Qing WG, Conti CJ, LaBate M, Johnston D, Slaga TJ, MacLeod MC (1997) Induction of mammary cancer and lymphoma by multiple, low oral doses of 7, 12-dimethylbenz(a)anthracene in SENCAR mice. *Carcinogenesis* 18(3):553–559
- Rao KVN, Detrisac CJ, Steele V, Hawk ET, Kelloff GJ, McCormick DL (1996) Differential activity of aspirin, ketoprofen and sulindac as cancer chemopreventive agents in the mouse urinary bladder. *Carcinogenesis* 17:1435–1438
- Reynolds P, Hurley SE, Gunier RB, Yerabati S, Quach T, Hertz A (2005) Residential proximity to agricultural pesticide use and incidence of breast cancer in California, 1988–1997. *Environ Health Perspect* 113:993–1000
- Rudel RA, Attfield KR, Schifano JN et al (2007) Chemicals causing mammary gland tumors in animals signal new directions for epidemiology, chemicals testing, and risk assessment for breast cancer prevention. *Cancer* 109(12):2635–2666
- Ueda M, Imai T, Takizawa T et al (2005) Possible enhancing effects of atrazine on growth of 7,12-dimethylbenz(a)anthracene-induced mammary tumors in ovariectomized Sprague-Dawley rats. *Cancer Sci* 96:19–25
- USEPA—U.S. Environmental Protection Agency (2003) Reregistration eligibility decision for Diuron. List A. Case 0046 Office of prevention, pesticides and toxic substances USEPA. Washington, DC, p 106
- USEPA—U.S. Environmental Protection Agency (2004) Chemicals Evaluated for Carcinogenic Potential Office of Pesticide Programs Health Effects Division, Science Information Management Branch 22
- Valentovic MA, Yahia T, Ball JG, Hong SK, Brown PI, Rankin GO (1997) 3, 4-dichloroaniline acute toxicity in male Fischer 344 rats. *Toxicology* 124:125–134
- Van Boven M, Laruelle L, Daenens P (1990) HPLC analysis of diuron and metabolites in blood and urine. *J Anal Toxicol* 14:231–234
- Verheij ER, van der Greef J, La Vos GF, van der Pol W, Niessen WM (1989) Identification of Diuron and four of its metabolites in human postmortem plasma and urine by LC/MS with a moving-belt interface. *J Anal Toxicol* 13:8–12
- Vinggaard AM, Breinholt V, Larsen JC (1999) Screening of selected pesticides for estrogen receptor activation in vitro. *Food Addit Contam* 16:533–542
- Vinggaard AM, Hnida C, Breinholt V, Larsen JC (2000) Screening of selected pesticides for inhibition of CYP19 aromatase activity in vitro. *Toxicol In Vitro* 14:227–234



**Figura 1**



Universidade Estadual Paulista  
Faculdade de Medicina de Botucatu

Distrito Rubião Junior, s/nº - Botucatu – S.P.

CEP: 18.618-970

Fone/Fax: (0xx14) 6802-6143

e-mail secretaria: capellup@fmb.unesp.br

Instituída na Faculdade de Medicina através da Portaria do Diretor nº 30 de 26/04/99



Comissão de Ética em Experimentação Animal

## CERTIFICADO

*CERTIFICAMOS que o Protocolo n.º 523 sobre o Projeto de Pesquisa “Avaliação da carcinogenicidade do pesticida Diuron [3,(3,4-diclorofenil) 1,1 dimetil uréia] em modelo experimental de carcinogênese mamário”, sob a responsabilidade do Prof. Dr. Luis Fernando Barbisan, com a colaboração de Tony Fernando Grassi, e do Prof. Dr. João Lauro Viana de Camargo, esta de acordo com os Princípios Éticos na Experimentação Animal adotado pelo Colégio Brasileiro de Experimentação Animal (COBEA), com a ressalva de que os ratos são provenientes de biotério convencional sem condições de emitir Atestado de Sanidade.*

*Projeto de Pesquisa Aprovado em 22 de março de 2.006*

**Profª Drª Norma Sueli P. Modolo**  
Presidente da CEEA

**Alberto Santos Capelluppi**  
Secretário da CEEA

PROGRAMA DE PÓS-GRADUAÇÃO EM PATOLOGIA  
DEPARTAMENTO DE PATOLOGIA  
FACULDADE DE MEDICINA

BOTUCATU, SP - RUBIÃO JÚNIOR - CEP 18618-970 PBX (014) 6802- 6238



Botucatu, 13 de janeiro de 2010

Ilma Sr<sup>a</sup>

Regina Helena Garcia Martins

Presidente da Comissão de Ética em Experimentação Animal

Prezada Sra.:

Vimos por meio deste, solicitar alteração do título do Projeto de Pesquisa **“Avaliação da carcinogenicidade do pesticida Diuron [3, (3,4-diclorofenil) 1,1 dimetil uréia] em modelo experimental de carcinogênese mamária”** sob a responsabilidade do Prof. Dr. Luis Fernando Barbisan com a colaboração de Tony Fernando Grassi e do Prof. Dr. João Lauro Viana de Camargo correspondente ao **Certificado nº 523** aprovado em 22 de março de 2006 pela Comissão de Ética em Experimentação Animal – Universidade Estadual Paulista – Faculdade de Medicina de Botucatu – UNESP para o título **“Carcinogênese de mama em modelo experimental de exposição gestacional, juvenil e adulta ao herbicida Diuron [3, (3,4-Diclorofenil) 1,1, dimetil uréia] em fêmeas Sprague-Dawley”**

Atenciosamente

Prof. Dr. Luis Fernando Barbisan

Orientador

Tony Fernando Grassi

Doutorando

163  
13/01/2010 09:09:00 COMITE DE ETICA EM PESQUISA FMS - UNESP



Universidade Estadual de Campinas - UNICAMP  
 Centro Multidisciplinar para Investigação Biológica na  
 Área da Ciência em Animais de Laboratório - CEMIB  
 International Council For Laboratory Animal Science  
 ICLAS Network Member for Promotion of Animal Quality in Research  
[www.cemib.unicamp.br](http://www.cemib.unicamp.br)



Prof. Dr. Tony Fernando Grassi  
 Faculdade de Medicina de Botucatu - UNESP  
 Departamento de Patologia - TOXICAM  
 Botucatu - SP

### Atestado de Saúde Animal

Atestamos que os ratos heterogenéticos da linhagem **NTacUnib:SD**, provenientes da Expansão de Matrizes S.P.F. (Specific Pathogen Free) deste Centro, pertencem à categoria sanitária S.P.F. e apresentam-se isentos dos agentes patogênicos pesquisados pelo laboratório de controle de qualidade sanitária. Informamos que os mesmos encontram-se livres de outros agentes infecciosos capazes de causarem riscos à saúde humana. No atestado consta a data dos últimos testes do programa de monitorização sanitária, rotineiramente realizados pelo Laboratório de Controle de Qualidade Animal - C.Q.S. (\*).

**Observação** - O estado sanitário dos animais retirados do CEMIB nesta data será mantido se os mesmos forem acondicionados em equipamento adequado e o mesmo não for violado durante o transporte. A Instituição receptora deverá oferecer infra-estrutura e condições adequadas para a manutenção de animais da Categoria Sanitária livres de agentes patogênicos especificados (S.P.F.), alojando os animais em equipamentos e/ou salas dotadas de sistema de barreiras de proteção sanitária. Torna-se necessário manejo correto e a esterilização de todo material utilizado na rotina como: ração, maravalha/cama, bebedouros, água, gaiolas, tampas, e outros.

(\*) Data dos últimos testes de monitorização sanitária realizados: Março/2009.

Campinas, 11 de maio de 2009.

Drª. Delma Pegolo  
 Diretora - Cemib/Unicamp  
 E-mail: [diretoria@cemib.unicamp.br](mailto:diretoria@cemib.unicamp.br)

Dr. Rovilson Gilioli  
 Controle de Qualidade Animal  
 E-mail: [sanitario@cemib.unicamp.br](mailto:sanitario@cemib.unicamp.br)




Figura 2




Figura 3